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Targeting primary cilia-mediated mechanotransduction to promote whole bone formation 
Milos Spasic 
 
Osteoporosis is a devastating condition characterized by decreased bone mass, and affects 
over 50% of the population over 50 years old. Progression of osteoporosis results in significantly 
heightened risk of fracture leading to loss of mobility, prolonged rehabilitation, and even 
mortality due to extended hospitalization. Current therapeutic options exist to combat low bone 
mass, but these treatments are being met with increasing concern as reports emerge of atypical 
fractures and necrosis. Thus, new therapeutic strategies are required. 
Bone is highly dynamic, and it has long been known that physical load is a potent 
stimulus of bone formation. Despite this, none of the current treatments for bone disease leverage 
the inherent mechanosensitivity of bone – the ability of bone cells to sense and respond to 
mechanical forces such as exercise. One potential therapeutic target is the primary cilium. 
Primary cilia are solitary antenna-like organelles, and over the last 20 years have been identified 
as a critical cellular mechanosensor. Primary cilia and cell mechanotransduction are critical to 
the function of numerous cells and tissues. Thus, understanding primary cilia-mediated 
mechanotransduction has potential applications in treating kidney and liver disease, 
atherosclerosis, osteoarthritis, and even certain cancers. Previous work from our group has 
 ii 
demonstrated that disruption of the cilium impairs bone cell mechanosensitivity, resulting in 
abrogated whole bone adaptation in response to physical load.  
In this thesis we examine the potential of targeting the primary cilium to enhance bone 
cell mechanosensitivity and promote whole bone formation. First, we demonstrate the 
pharmacologically increasing primary cilia length significantly enhances cell 
mechanotransduction. Next, we expand our list of candidate compounds to manipulate 
ciliogenesis through the use of high-throughput drug screening. We developed an automated 
platform for culturing, staining, imaging, and analyzing nearly 7000 small molecules with known 
biologic activity, and classify them based on mechanism of action. One of these compounds is 
then used in a co-culture model to study the effects of manipulating osteocyte primary cilia-
mediated mechanosensing on pro-osteogenic paracrine signaling to promote the activity of bone-
forming osteoblasts and osteogenic differentiation of mesenchymal stem cells. Finally, we 
translate our in vitro findings into an in vivo model of load-induced bone formation using the 
same compound to enhance cell mechanotransduction. We demonstrate that we can sensitize 
bones to mechanical stimulation to enhance load-induced bone formation in healthy and 
osteoporotic animals, with minimal adverse effects. Together, this work demonstrates the 
therapeutic potential and viability of targeting primary cilia-mediated mechanotransduction for 
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Medical advances are resulting in humans living longer than ever; however, these 
patients are now increasingly being met with skeletal deficiencies and abnormalities. 
Osteoporosis is the most prevalent of these conditions, and is marked by a decrease in bone mass 
resulting in heightened risk of fracture. In fact, over 50% of the US population over 50 years old 
are affected by osteoporosis impacting the lives of over 50 million men and women in the US, 
and over 200 million women alone worldwide 1. It is expected that the number of Americans 
over 65 is expected to double by 2060, and the incidence of hip fractures in men and women is 
estimated to rise 310% and 240%, respectively, between 1990 and 2050 2. Hip fractures 
represent the most devastating result of osteoporosis, with 20% patient mortality within the first 
year following fracture 3,4. Surviving patients are still left with dramatically impaired quality of 
life, with 60% requiring extra assistance, and 33% entirely reliant on caretakers, leaving less than 
7% reaching full recovery 5,6. Direct medical costs of osteoporotic fractures in the US alone are 
estimated to be over $20 billion per year, and are expected to rise to $50 billion by 2050 7. The 
World Health Organization considers osteoporosis to be the second greatest health concern 
following cardiovascular disease, and the disability caused by osteoporosis to been classified as 
more significant than that produced by cancers and chronic non-transferable pathologies 7,8. 
While the majority of the burden of bone diseases is due to conditions marked by low bone mass, 
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several rare bone diseases, such as osteopetrosis (1 in 100-500k people) and melorheostosis (1 in 
1.1 million people), present with excessive bone formation 9,10. 
It has long been known at mechanical stimulation is a potent anabolic stimulus of bone 
formation. Julius Wolff first described that bone actively responds to mechanical load, becoming 
stronger to prevent fracture from that sort of loading 11. This is phenomenon is clearly witnessed 
in active versus sedentary people, and is most notable in tennis and baseball players, whose 
dominant arms exhibit drastically greater bone density compared to non-dominant arms 12. 
Conversely, absence of load results in reduced bone mass, heightening susceptibility to fracture 
as experienced with astronauts and sedentary patients, as well as less mobile elderly patients 13.  
 
1.2. Bone and current therapeutics 
Bone is a dynamic organ system, constantly responding to external stimuli. Chemical 
stimuli such as parathyroid hormone signaling, vitamin D, calcitonin, or calcium signaling can 
elicit formation or resorption of bone tissue 14. The work in this thesis, however, focuses on the 
mechanosensitivity of bone.  
Within bone, the three predominant cell types are osteoclasts, osteoblasts, and osteocytes. 
Osteoclasts are the bone resorbing cells. These are multinucleated cells which secrete digestive 
enzymes to break down mineralized bone tissue. Osteoblasts are the primary bone forming cells, 
producing matrix proteins such as collagen I and osteopontin, as well as mineral apatite as the 
foundation of new bone 14. Osteocytes are considered the signaling cells within bone. As 
osteoblasts age and become more embedded in cortical bone, they become osteocytes. These 
cells reside in fluid-filled pockets within bone called lacunae, connected via canaliculi. The 
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lacunar-canalicular network allows for osteocytes to sense chemical and physical stimuli, and 
efficiently communicate with each other and other bone cells. Thus, the osteocyte is viewed as a 
nexus coordinating signaling between osteoblasts and osteoclasts to regulate bone formation, 
resorption, and overall skeletal maintenance. For example, osteocytes secrete RANKL (receptor 
activator of nuclear factor kappa-B ligand) to stimulate osteoclast activity, and OPG 
(osteoprotegerin) to prevent RANKL binding and inhibit osteoclast activation 14. Osteoblast 
activity can be regulated by osteocyte secretion of PGE2 (prostaglandin E2), ATP (adenosine 
triphosphate), and NO (nitric oxide). Osteocytes also secrete sclerostin, which acts as a negative 
regulator of osteoblastic bone formation 15. Many bone diseases such as osteoporosis result from 
an imbalance of the normal signaling between osteocytes, osteoblasts, and osteoclasts.  
Though existing first-line therapeutics are available and have demonstrated reasonable 
success in mitigating the effects of osteoporosis, they present significant limitations. 
Bisphosphonates are the current gold standard and prevent osteoclasts from resorbing bone 
material, resulting in increased accumulation of microdamage within bone 16. Clinically, 
bisphosphonates have been met with increased risk of atypical fracture and mandibular necrosis 
17,18, leading to a drastic change in patient sentiment to that of fear of medical intervention. 
Media reports of atypical jaw and long bone fractures have in large part caused the 50% decrease 
in bisphosphonate prescriptions between 2008 and 2012 19. Due to the current patient discomfort 
with current treatment options, it is estimated that after one year only 40% of patients will 
continue with their prescribed treatment, and after two years only 20% will continue treatment, 
demonstrating a need for new therapeutic options 20,21. RANKL inhibitors comprise the next in 
line treatment option, but similarly inhibit osteoclast activity, and can result in similar adverse 
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effects as bisphosphonates. Amgen is in phase III trials with an antibody against sclerostin, 
preventing normal inhibition of osteoblast activity. However, reports suggest this may not be a 
feasible long-term strategy and may result in certain cancers 22. Due to these concerns with 
existing therapeutics, there is a significant need for a new class of bone therapeutic.  
 
1.3. Methods of mechanotransduction 
Mechanotransduction is the process by which cells sense and respond to their mechanical 
environment and external physical forces. Mechanical stresses direct and dictate cell and tissue 
functions throughout the entire lifespan of an organism. Growing work, in a number of different 
cell and tissue types, as well as organisms, has helped uncover the mechanisms of cellular 
mechanotransduction. Within the cell, several different mechanosensing mechanisms exist, often 
working in concert producing a range of responses – from short-term changes such as 
cytoskeletal reorganization, to long-term gene expression and epigenetic modifications. These 
mechanosensing mechanisms can include the cytoskeleton, cell membrane mechanics, the 
glycocalyx, focal adhesions, adherens junctions, caveolae, deformation of the nucleus, and 
primary cilia 23. Together these mechanotransduction pathways allow cells to adapt to changing 
mechanical environments, modulating whole tissue function, morphology, and remodeling. 
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Figure 1.1: Mechanisms of cellular mechanotransduction 
Cells experience several different types of mechanical stimulation. This can include, but is not limited to, fluid shear 
across the apical surface of the cell, as well as compression and tension generated by fluid pressure and extracellular 
matrix/tissue deformation. These forces may be sensed by any combination of adherens junctions (a), the glycocalyx 
(b), membrane mechanics (c), the cytoskeleton (d), focal adhesions (e), deformation of the nucleus (f), caveolae (g), 
and primary cilia (h) 23. 
 
The three basic mechanical stresses acting on cells are tension, compression, and shear, 
Fig. 1.1. For example, tendon and ligaments sustain large tensile stresses, arteries are stretched 
and sheared from the pulsatile blood flow, and bones resist compressive and tensile stresses. But 
the predominant stress is not always the most important stimulus for cells. In bone, the strains 
induced by physiological compression are very small (on the order of 2,000 microstrain) yet 
bone cells in vitro respond to strain on the order of 30,000 microstrain, suggesting that whole 
bone strain is amplified at the cellular level 2. Indeed, the current paradigm is that small strains 
squeeze interstitial fluid flow through a network of small channels, the canaliculi, much as a 
sponge does when a load is applied. The moving fluid leads to shear stress, and the magnitudes 
of shear stress estimated to occur physiologically in these channels have been shown to be potent 










absence of strain has been shown to induce bone formation 5. It is therefore crucial to understand 
the environment of the cell to know which type of stress is acting on the cell and which temporal 
patterns and magnitudes of stimulation elicit a cellular response. 
 
1.4. Primary cilia 
While cells utilize numerous different mechanisms to sense and respond to mechanical 
stimulation, the work in this thesis focuses on primary cilia-mediated mechanotransduction. 
 
Primary cilia structure 
The primary cilium is a single immotile organelle protruding from the apical surface of 
nearly all mammalian cells 24. Primary cilia share similar structural characteristics with motile 
cilia, both consisting of 9 microtubule doublets forming the ciliary axoneme. Motile cilia, 
however, also contain a central microtubule doublet, radial spokes, and a nexin ring, allowing for 
cellular functions, such as propulsion or clearing of mucus and debris, not experienced in 
primary cilia. While primary cilia were identified in mammalian cells over 100 years ago, they 
were long considered vestigial structures. Recently improved molecular and biochemical 
techniques have enabled keen insights into this once forgotten organelle. Today, primary cilia are 
understood to play a critical role in the transduction of chemical and mechanical cues. In 
addition, primary cilia have been implicated as a nexus for numerous signaling pathways critical 




Figure 1.2: Primary cilia structure 
Primary cilia have three major zones, the axoneme, the transition zone and the basal body. The axoneme is 
comprised of 9 microtubule doublets and is surrounded by the ciliary membrane, while the basal body contains 9 
microtubule triplets. Anterograde IFT (intraflagellar transport) allows delivery of cargo towards the distal tip 
through kinesin-2, while IFT-dynein is responsible for retrograde transport. The microtubules within the cilium are 
heavily acetylated, contributing to their bending stiffness. Furthermore, the cilium forms a microdomain distinct 
from the rest of the cell to which specific proteins are trafficked. This is done through a diffusion barrier, excluding 
large (80-100 kDa) proteins from freely diffusing in or out of the cilium, thought to exist either in the transition zone 




Impairment of primary cilia function and ciliary associated proteins has been identified as 
the cause of numerous different conditions known as ciliopathies. Polycystic kidney disease can 
result from genetic mutations in Pkd1 and Pkd2, coding for the PC1/2 mechanosensitive ion 
channel complex 28. Bardet-Biedl Syndrome (BBS) is characterized by renal failure, polydactyly, 
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and retinitis pigmentosis, and is caused by mutations in ciliary associated BBS proteins 29. 
Retinal and skeletal conditions, such as Joubert and Meckel-Grouber Syndromes, are also 
attributed to cilia dysfunction 24,30. Primary cilia have also been suggested to have a potential role 
in cystic and fibrotic liver disease, atherosclerosis, bone maintenance, and osteoarthritis, as 
described in the following section. The growing list of ciliopathies and cilia-associated 
conditions has stimulated further research into the vast array of roles of the primary cilium. 
While primary cilia do serve as chemosensors 31, this thesis focuses on their 
mechanosensory capabilities. Mechanical loading may result in a variety of physicochemical 
stimuli, such as changes in osmolarity, hydrostatic pressure, and pH, which may be sensed by the 
primary cilium 32,33. The prevailing theory is that mechanical stimulation, such as fluid flow or 
tissue deformation, causes primary cilia deflection to initiate downstream mechanotransduction 
signaling cascades. 
 
Ciliary protein localization 
Numerous proteins, such as PC1, PC2, TRPV4, and AC6, localize to the primary cilium 
and have been identified as critical for mechanotransduction 34–36. The localization of stretch-
activated ion channels such as PC2 and TRPV4 suggest that their activation in response to fluid 
shear induces changes in ion concentrations within the cilium that initiate mechanotransduction 
signaling cascades. This signaling cascade is continued through proteins converting these ion 
changes into second messengers, with one hypothesis being that AC6 is inhibited by calcium 
increases to decrease cAMP levels, altering downstream PKA signaling and CREB-mediated 
transcriptional regulation 36,37. 
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Intracilliary calcium signaling 
 It is believed that deflection of the primary cilium opens the stretch-activated ion 
channels localized to the ciliary membrane, initiating calcium flux into the ciliary microdomain, 
resulting in downstream signaling cascades to the rest of the cell. Recent advances in molecular 
techniques have enabled several groups to develop fluorescently encoded calcium biosensors that 
specifically localize to the primary cilium. First, Work by Su et al. (2013) demonstrated that 
fusing the 5HT6 cilia-targeted protein to a genetically encoded calcium indicator (circularly 
permuted GFP located between M13, light chain kinase, and CaM, calmodulin, domains) allows 
for examination of calcium transients within the ciliary microdomain 38. This allowed 
measurements of fluid flow-induced calcium increases specifically within the cilia of kidney 
epithelial cells. Jin et al. (2014) then demonstrated similar results using a distinct ciliary-targeted 
calcium biosensor 39. These results were coupled with cytoplasmic calcium measurements, 
recording ciliary calcium changes that precede those in the cytoplasm, suggesting that ciliary 
calcium entry could initiate mechanotransduction events. Our group recently utilized a FRET-
based biosensor (fluorescence resonance energy transfer) targeted to the cilium using Arl13b in 
both osteocytes and kidney epithelial cells 35. Again, measured ciliary calcium transients 
preceded cytoplasmic calcium changes.  
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1.5. Primary cilia-mediated mechanotransduction in various cell 
and tissue types 
While it is known that bone actively responds to mechanical stimulation, it is 
incompletely understood how cells sense and respond to these applied physical forces – 
mechanotransduction. Much of our understanding of primary cilia-mediated mechanosensing in 
bone is derived from studying other cell and tissue types. The primary cilium is involved in 
mechanosensing in a wide range of cell and tissue types. These various tissues all require 




Primary cilia play a critical role in embryonic development. In fact, global deletion of 
proteins required for formation of primary cilia, such as IFT88 (intraflagellar transport 88; 
required for transport of cargo within the cilium) or Kif3a (kinesin family member 3A; a motor 
protein subunit required for cilia formation), is embryonic lethal 40,41. During development, 
motile cilia within the embryonic node actually begin to move and generate directional flow of 
extracellular fluid, which is sensed by non-motile primary cilia in the surrounding crown cells 
40,42. These cilia working in tandem results in proper left-right differentiation, and impairing 
either primary or motile ciliary function disrupts embryogenesis. Primary and motile cilia have 






Much of the early work describing primary cilia mechanotransduction was conducted in 
kidney cells 43,44. Proper kidney function is dependent on regulated fluid flow through the 
nephrons and collecting ducts to control glomerular filtration rate, and this flow is sensed by 
kidney epithelial cell primary cilia 45,46. Deflection of the primary cilium, by both fluid flow and 
micropipette manipulation, induces an increase in intracellular calcium, in a primary cilia-
dependent manner 44,46,47. This calcium influx is also mediated by the PC1/2 ion channel 
complex 46. PC1 and PC2 both localize to the primary cilium, where PC1 is a mechanosensitive 
membrane protein regulating the opening of the PC2 channel 48. In addition to calcium signaling, 
PC1 has been implicated in direct activation of STAT (signal transducer and activator of 
transcription) to regulate gene expression, demonstrating the potential for mechanotransduction 
pathways distinct from calcium 49–51. In renal cells, functional defects of either portion of this ion 
channel complex, along with complete disruption of cilia formation, result in polycystic kidney 
disease 52.  
 
Endothelia 
Endothelial cells sense blood flow and regulate vessel diameter to maintain blood 
pressure  53. The shear stress stimulates endothelial nitric oxide production, an important 
vasodilator, and endothelial primary cilia have been implicated as important mechanosensors that 
regulate nitric oxide production 54,55. Furthermore, PC1/2 has been identified as a critical 
component for this mechanotransduction response to occur, with cells lacking this ion channel 
complex exhibiting an attenuated response to fluid flow 54. Mice lacking PC1 display decreased 
 12 
serum nitric oxide leading to a hypertensive phenotype 56. Similarly to kidney epithelial cells, 
chemical removal of primary cilia, using chloral hydrate, in endothelial cells abrogates the 
response to flow 57. Interestingly, in vivo, endothelial cilia are only present at areas of low shear 
stress, potentially as a means to sensitize cells to lower amounts of mechanical stimulation 57,58. 
Furthermore, flow sensing primary cilia appear to be more prevalent at atherosclerotic 
predilection sites where shear stresses are low and disturbed 59. Removal of endothelial primary 
cilia impairs nitric oxide signaling resulting in increased atherosclerotic plaque formation 60.  
 
Liver 
Similarly to endothelial and renal epithelial cells, cholangiocyte primary cilia detect fluid 
flow in the bile duct 37. Fluid flow through isolated intrahepatic bile duct units results in a similar 
calcium influx as in renal cells, as well as a decrease in intracellular cAMP – responses which 
are cilium dependent 37,44. Cilia-localized PC1 and PC2 are necessary for this flow induced 
calcium increase and cAMP decrease. Furthermore, adenylyl cyclase 6 (AC6), which converts 
ATP into the second messenger cAMP, is calcium inhibited and localizes to cholangiocyte 
primary cilia 37. Mutations to these proteins can impair mechanotransduction, resulting in several 
cholangio-ciliopathies such as cystic and fibrotic liver disease 61. It has also been identified that 
ciliogenesis is heterogenous between larger and smaller bile ducts; however it is not yet clear if 
this is due to spatial limitations or to optimize primary cilia-mediated mechanosensing to varying 





Chondrocytes actively respond to cartilage compression and deformation, and moderate 
loading may slow the progression of osteoarthritis 62. Chondrocyte cilia, however, may have a 
distinct structure from previously mentioned flow sensors. Extracellular matrix binding proteins 
and integrins both localize to chondrocyte cilia, suggesting that these cilia may not be flow 
sensors, but rather directly sense local tissue deformation 63. Mechanical stimulation of 
chondrocytes initiates an up-regulation of proteoglycan and aggrecan synthesis, but this response 
is abrogated in cells lacking primary cilia 64. In addition, chondrocytes display a significant 
calcium influx in response to hypoosmotic loading, a response that is lost with chemical removal 
of primary cilia by chloral hydrate treatment 65. Interestingly, chondrocytes lacking primary cilia 
still display mechanically induced ATP release to initiate intercellular calcium signaling, a 
response that is lost in cilia-deficient epithelial cells – suggesting the potential for multiple and 
distinct mechanotransduction processes in different cell types 64. Compressive loading increases 
chondrocyte matrix deposition, in a response that is mimicked with treatment with an agonist 
(GSK1016790A) of the ciliary ion channel, TRPV4 66. These works demonstrate that 
chondrocyte cilia are not exclusively flow sensors, but may also respond to compressive and 
osmotic loading conditions. Chondrocyte primary cilia may also play a role in organizing cell 
polarity. In the growth plate, chondrocytes organize in columnar stacks that become completely 
disorganized with primary cilia disruption by Kif3a knockout 67. This cell and cilia organization 
may optimize the cells to sense mechanical stimulation, in a manner similar to tenocytes within 
tendon 68; however, the specific mechanosignaling function of primary cilia in tendon has not yet 
been characterized to the same degree as the previously mentioned cell types. 
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Cancer 
Recently, primary cilia mechanosensing has been associated with tumor progression. 
Increased interstitial pressure and fluid flow have been described in a number of cancers, but 
how these biophysical effects are sensed and transduced to regulate tumor progression are 
incompletely understood 69. Primary cilia facilitate Hedgehog (Hh) and Wnt signaling pathways 
which help direct cell proliferation 24. Mutations or irregular stimulation of Hh and Wnt 
signaling are instrumental in the progression of numerous cancers 70,71. Furthermore, both Hh 
and Wnt signaling can be modulated by the presence or absence of fluid flow mechanical 
stimulation, as well as alterations in cilia structure 72–74. Breast, prostate, and liver cancer cells 
experience a decrease in primary cilia incidence through tumor progression, and recovery of cilia 
incidence by HDAC6 inhibition has been shown to slow progression of cholangiocarcinoma 75,76. 
In contrast, basal cell carcinomas are actually frequently ciliated and removal of primary cilia 
can inhibit tumor formation, demonstrating multiple roles of cilia in cancer progression 77. 
Primary cilia formation is related to, but exclusive from, cell proliferation and senescence, as 
ciliogenesis occurs upon entry of the cell into the G0 phase of the cell cycle 78. Thus, 
manipulating ciliogenesis provides potential to regulate tumor cell growth. Many tumors are also 
characterized by an increase in tissue stiffness, with associated mechanotransduction events 
causing translocation to the nucleus of YAP (Yes-associated protein) and TWIST transcription 
factors 79,80. Altering matrix rigidity, however, can slow growth and metastasis demonstrating 
that cancerous cells are indeed mechanosensitive, yet it is not completely clear what role primary 
cilia have in direct sensing of the tumor mechanical environment. While it is incompletely 
understood how ciliogenesis dictates tumor mechanosensing and growth, evidence is mounting 
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that targeting primary cilia-mediated signal transduction may be a therapeutic strategy to slow 
tumorigenesis. 
 
1.6. Primary cilia in bone 
Osteocytes are considered the primary mechanosensing cells within bone, detecting fluid 
flow through the lacunar-canalicular network 81. Within these cells, the primary cilium has been 
identified as a critical mechanosensor, both in vitro and in vivo 82,83. Mice with an osteoblast and 
osteocyte specific deletion of primary cilia, Kif3a-/- (a motor protein subunit required for cilia 
formation), exhibit a reduction in load-induced bone formation 83. It has also been revealed that 
PC1 plays a significant role in osteocyte mechanosensing. Xiao et al. (2011) utilized a Dmp1-
driven Cre mouse model to conditionally disrupt Pkd1 in osteocytes 84. When subjected to 
mechanical loading, the Pkd1 deficient mice displayed reduced load-induced bone formation, 
suggesting that PC1 plays an important role in bone cell mechanotransduction. Mutations to 
another cilia-localized mechanosensitive ion channel, TRPV4, results in a wide range of skeletal 
dysplasias 85. As in cholangiocytes, AC6 is also found in the osteocyte primary cilium, and fluid 
flow induces an increase in intracellular calcium and a decrease in cAMP, in a process mediated 
by AC6 36. In vivo, AC6 knockout mice display no phenotypic difference in bone 
microarchitecture compared to wildtype mice, but when subjected to mechanical load, the AC6-/- 
mice have an attenuated bone formation response 86. Primary cilia-mediated 
mechanotransduction has even been implicated in healing around a bone implant, with mice 
lacking primary cilia within bone displaying impaired cell mechanosensitivity and osteogenesis 
in the peri-implant space 87. 
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1.7. Overall goal of this thesis 
The overall goal of this thesis is to demonstrate primary cilia as a viable target for 
sensitizing cells to mechanical stimulation, in an effort to guide the development of novel 
osteoporosis therapeutics. The overall hypothesis is that by increasing primary cilia length cells 
will become more mechanosensitive, resulting in an enhanced osteogenic response to external 
physical stimuli. The rationale for this is that increasing primary cilia length will enhance 
production of ciliary mechanosensing proteins, and also increase ciliary bending in response to 
mechanical stimulation to further activate ciliary ion channels. Together, these biochemical and 
structural changes will potentiate mechanotransduction events. 
 
 
Figure 1.3: Increasing primary cilia length will potentiate cellular mechanosensing 
Increasing primary cilia length is hypothesized to have two effects. 1) increasing length will enhance production of 
ciliary mechanosensitive proteins such as AC6. 2) increased cilia length could allow increased bending of the cilium 
to further stimulate stretch activated ion channels localized to the ciliary membrane.  
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Chapter 2 
2. Lengthening primary cilia enhances cell 
mechanotransduction 
2.1. Abstract 
The primary cilium is a mechanosensor in a variety of mammalian cell types, initiating 
and directing intracellular signaling cascades in response to external stimuli. When primary cilia 
formation is disrupted, cells have diminished mechanosensitivity and an abrogated response to 
mechanical stimulation. Due to this important role, we hypothesized that increasing primary cilia 
length would enhance the downstream response, and therefore, mechanosensitivity. To test this 
hypothesis, we increased osteocyte primary cilia length with fenoldopam and lithium and found 
that cells with longer primary cilia are more mechanosensitive. Furthermore, fenoldopam 
treatment potentiated adenylyl cyclase activity and was able to recover primary cilia form and 
sensitivity in cells with impaired cilia. This work demonstrates that modulating the structure of 
the primary cilium directly impacts cellular mechanosensitivity. Our results implicate cilium 
length as a potential therapeutic target for combating numerous conditions characterized by 





Bone cell mechanotransduction has been studied through several different mechanisms. 
Altering cytoskeletal mechanics by disruption of actin polymerization with cytochalasin D 
inhibits flow-induced osteogenic differentiation of C3H10T1/2 mesenchymal stem cells 88. 
Similar experiments in osteoblasts treated with cytochalasin D and exposed to fluid flow 
demonstrated increased cellular mechanosensitivity, as measured by prostaglandin E2 release 
82,89. Integrins couple the extracellular matrix with the cytoskeleton through focal adhesions 
comprised of actin-associated proteins such as talin and vinculin, and inhibition of focal adhesion 
dynamics impairs mechanosensitivity in response to fluid shear 90,91. Mathematical models of 
osteocytes in vivo estimate that osteocyte dendritic processes may experience higher strain than 
the cell body 92. In a separate study, a transwell filter system was used to differentiate the 
osteocyte cell body and dendritic processes, and each were mechanically loaded separately 93. It 
was found that the glycocalyx of the dendritic processes is critical in forming integrin 
attachments that initiate a mechanotransduction pathway that results in the opening of 
hemichannels on the cell body. Gap junctions between adjacent cells are thought to contribute to 
mechanotransduction by mediating calcium, ATP, and prostaglandin E2 intercellular signaling 
94. Membrane deformations also play a significant role in cell mechanosensing where stretch-
activated channels, such as polycystin-2 (PC2) and transient receptor potential vanilloid 4 
(TRPV4), mediate calcium influx to initiate mechanotransduction 35,48,65. 
Osteocytes are mechanosensitive cells within bone, and previously, we have 
demonstrated that the primary cilium functions as a mechanosensor in this context 82. Fluid flow 
mechanical stimulation of osteocytes in vitro enhances expression of the osteogenic genes 
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cyclooxygenase-2, COX-2, and osteopontin, OPN. COX-2 synthesizes prostaglandin E2, and 
OPN is a critical extracellular matrix protein. Increases in the production of both are indicative of 
osteogenesis 95–98. When osteocyte primary cilia formation is inhibited, the cells display an 
abrogated osteogenic response to flow, implicating the cilium as a critical mechanosensor in 
osteocytes 82. Furthermore, we have previously reported that adenylyl cyclases, specifically AC6, 
play a significant role in osteocyte mechanosensitivity 36. Adenylyl cyclases convert ATP to the 
ubiquitous second messenger cAMP, a process which can be specifically stimulated by forskolin.  
Despite prior in vitro work, the role of osteocyte primary cilia in vivo is yet unclear. The 
presence of primary cilia within mineralized bone has been addressed with conflicting reports. 
Tonna and Lampen found that less than 4% of osteocytes possessed primary cilia, while 
Uzbekov et al. reported greater than 94% incidence 99,100. Furthermore, the lacunar space within 
which osteocytes reside suggests that primary cilia are less than 1 µm long, as opposed to in vitro 
lengths which can be 4 µm 82,101. A recent fluid-structure interface model was developed to 
estimate how primary cilia may deform in vivo 92. It was concluded that a short cilium, 
approximately 0.2 µm, was not long enough to be a mechanosensor, but that an elongated cilium 
spanning the full pericellular space could be. We have previously utilized a mouse model where 
primary cilia were deleted from osteocytes and osteoblasts, resulting in impaired 
mechanotransduction and abrogated load-induced bone formation 83. While the specific 
orientation, and even incidence, of osteocyte primary cilia in vivo remains unclear, evidence 
suggests that the cilium may yet play a key role in bone mechanosensing, and that modifying 
cilium structure may alter mechanotransduction. 
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While several small molecules exist to increase cilia length, in this work we utilize two 
drugs that are both clinically approved and have distinct mechanisms of action — fenoldopam, 
used to treat hypertension, and lithium, a treatment for bipolar disorder — to increase primary 
cilia length. Fenoldopam is a dopamine D1-like receptor agonist, and has previously been used to 
increase primary cilia length in endothelial cells and kidney epithelial cells, potentially through 
an adenylyl cyclase-cAMP mechanism 56,102. In the context of bone, MC3T3 osteoblasts express 
dopamine receptors 1-5, yet the role of specific dopamine receptors and the effects of 
fenoldopam treatment is unknown, and has never been examined in MLOY4 osteocytes 103. 
Analysis of gene expression patterns after tibial loading in adult rats reveals a wide array of 
upregulated genes, including dopamine D1 receptor mRNA 104. Interestingly, transgenic mice 
with a global deletion of this receptor have no apparent difference in bone architecture or 
calcification compared to controls 105. Mice with a homozygous deletion of the dopamine 
transporter have diminished bone mass, but the role of specific dopamine receptors was not 
examined 106.  Lithium is regularly used as an agonist of the Wnt signaling pathway in various 
cell types including MLO-Y4 osteocytes, and has been shown to increase primary cilia length in 
cultured fibroblasts and neurons through a yet incompletely characterized mechanism 107,108. In 
Lrp5 knockout mice, lithium treatment restores bone metabolism and bone mass, and activates 
Wnt signaling in isolated calvarial osteoblasts 109. Lithium and fenoldopam have distinct 
mechanisms of action and both increase primary cilia length in a variety of cell types, but their 
effects on primary cilia-mediated mechanotransduction in osteocytes has not been studied. 
Due to the significance of primary cilia in cellular mechanotransduction, we hypothesized 
that increasing their length would enhance mechanosensitivity. Here, we treat osteocytes with 
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lithium and fenoldopam to increase primary cilia length, and then mechanically stimulate the 
cells. We then examine the potential of targeting primary cilia length to recover impaired 
primary cilia-mediated mechanotransduction using models of impaired cilia and ciliary proteins. 
Our results highlight the importance of cilium length in cellular mechanosensitivity, and that this 
is a process that can be modulated by pharmacologic intervention. 
 
2.3. Materials and Methods 
2.3.1. Summary 
In this Chapter, we study how pharmacologic manipulation of primary cilia length 
impacts cellular mechanosensitivity. Osteocytes are treated with two distinct small molecules 
and exposed to oscillatory fluid flow as a mechanical stimulus, and resulting changes in mRNA 
expression are quantified. siRNA-mediated knockdown is also used to discern potential signaling 
pathways through which these changes in mechanosensitivity may occur. 
2.3.2. Cell culture and drug treatment 
MLO-Y4 osteocytes were cultured on collagen I-coated (Corning) dishes in MEMα (Life 
Technologies) supplemented with 5% fetal bovine serum (FBS), 5% calf serum (CS), and 1% 
penicillin/streptomycin (P/S) at 37°C and 5% CO2. Fenoldopam mesylate (Sigma) was used at 
10 µM diluted in DMSO, dimethyl sulfoxide, (Sigma) and normal culture media, as previously 
described 56,102. Lithium chloride (Sigma) was used at 500 µM diluted in normal culture media – 
a dose response from 50 µM to 10 mM was examined with 500 µM being the lowest dose to 
increase length significantly, data not shown. These agents, or their vehicle control, were applied 
to cells for 16 hours prior to experimentation. MTT, methylthiazolyldiphenyl-tetrazolium 
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bromide, assay (Sigma) was performed according to manufacturer’s protocol to assess cell 
viability with drug treatments. Phase contrast microscopy with an Olympus CKX41 inverted 
microscope and 40X objective was used to assess cell morphology. MLO-Y4 osteocytes used 
throughout this thesis were graciously donated by Dr. Lynda Bonewald. 
2.3.3. Immunocytochemistry 
For primary cilia imaging and analysis, cells cultured on collagen I-coated glass were 
fixed in 10% formalin and treated with anti-acetylated α-tubulin primary antibody, 1:1, from a 
C3B9 hybridoma cell line (Sigma). Cilia were visualized with Alexa-Fluor 488 secondary 
antibody, 1:1000, (Life Technologies), and imaged with a 100X oil objective on an Olympus 
Fluoview FV1000 confocal microscope. Nuclei were stained with DAPI (Life Technologies). 
Cilia lengths were analyzed using Image J. 
2.3.4. Oscillatory fluid flow 
Cells were exposed to oscillatory fluid flow as a mechanical stimulus. Cells were seeded 
on collagen I-coated glass slides at ~ 2800 cells/cm2 and cultured for 72 hours before application 
of flow. Drug treatments were applied 16 hours prior to experimentation. Slides were loaded into 
parallel plate flow chambers (dimensions: 75 x 38 x 0.28 mm) that we have previously described 
and allowed to incubate at 37°C for 30 minutes prior to initiation of stimulation 36,82,86. Flow was 
applied for 1 hour at 1 Hz with a peak flow rate of 18.8 ml/min, providing 1 Pa peak wall shear 
stress. 
2.3.5. mRNA expression 
Immediately after flow, cells were washed with PBS and total mRNA was isolated using 
TriReagent (Sigma). Total mRNA was converted to cDNA by TaqMan reverse transcriptase 
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(Applied Biosystems). Gene expression was analyzed by quantitative real-time PCR using 
primers and probes (Life Technologies) for analysis of cyclooxygenase-2, COX-2 
(Mm00478374_m1); osteopontin, OPN (Mm00436767_m1); adenylyl cyclase 6, AC6 
(Mm00475772_m1); intraflagellar transport 88, IFT88 (Mm00493675_m1); and GAPDH 
(4351309). Samples and standards were run in triplicate, and all gene expression was normalized 
to GAPDH endogenous control, as previously performed 36,86. 
2.3.6. RNA interference 
Gene silencing was performed by siRNA mediated knockdown, and compared to 
scramble siRNA control (Life Technologies). For primary cilia disruption, cells were transfected 
with 20 µM IFT88 siRNA (5′-CCAGAAACAGATGAGGACGACCTTT-3’), AC6 siRNA (5’-
CCTGCCACCTACAACAGCTCAATTA-3’). or scrambled siRNA control using Lipofectamine 
2000 (Life Technologies) as previously described 36. 
2.3.7. Adenylyl cyclase activity 
Adenylyl cyclase activity was quantified by cAMP ELISA (Enzo). Cells were cultured as 
previously described and treated with 10 µM fenoldopam for 16 hours. Cells were stimulated by 
10 µM forskolin (Sigma) or DMSO vehicle control for 20 minutes prior to lysis with 0.1 M HCl. 
Cell lysate was analyzed according to manufacturer’s protocol, and normalized to total protein 
quantified by BCA (Thermo Fisher). All samples and standards were run in duplicate. 
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Figure 2.1: Forskolin stimulates cAMP production by adenylyl cyclases 
Treatment with 10 µM Forskolin for 20 minutes stimulates adenylyl cylases to convert ATP (adenosine 
triphosphate) to cAMP (cyclic adenosine monophosphate), a critical second messenger within the cell. 
 
2.3.8. Analysis 
All data were analyzed with one-way ANOVA followed by Bonferroni post-hoc 
correction. Values are reported as mean ± SEM, with p < 0.05 considered statistically significant. 
Sample size, n, represents biological replicates. 
 
2.4. Results 
2.4.1. Increased cilia length with Fenoldopam and Lithium 
To test our hypothesis that cilium length directly affects mechanosensitivity, we first 
verified that we could modulate primary cilia length. We cultured MLO-Y4 osteocytes and 
treated them with two distinct small molecules to increase cilia length. Cells were cultured in 
media supplemented with fenoldopam, lithium, or vehicle control for 16 hours. 
Immunocytochemistry was used to image primary cilia and assess changes in cilia length. Both 
fenoldopam and lithium treatments induced significant increases in cilia length by 26% ± 7% and 
46% ± 5%, respectively, compared to vehicle control (Fig. 2.2A, B). Cell viability was assessed 
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with MTT assay and found no change effect of the drug treatments (Fig. 2.2C). Additionally, no 
gross morphological changes resulted from fenoldopam or lithium treatment (Fig. 2.2D, E). 
 
 
Figure 2.2: Small molecule treatments increase primary cilia length 
10 µM fenoldopam (A) and 500 µM Lithium (B) treatment for 16 hours significantly increases primary cilia length 
compared to vehicle control, with no changes in cellular morphology. Drug treatments elicited no change in cell 
viability, as assessed by MTT assay (C), and no gross morphological differences were exhibited (D, E). Mean ± 
SEM; n > 25 cilia for each group, n = 4 for MTT assay; **p < 0.01, ***p < 0.001; scale bars = 20 µm. 
 
2.4.2. Increased cilia length enhances cell mechanosensitivity 
Next, we examined the effect of elongating cilia on cellular mechanosensitivity by 
mechanically stimulating cells with longer cilia and analyzing their osteogenic response. 
Osteocytes were treated with fenoldopam, lithium, or vehicle control, and exposed to oscillatory 
fluid flow for 1 hr. As a control, samples were simultaneously loaded into flow chambers, but 
not subjected to flow. Mechanosensitivity was then quantified at the mRNA level with analysis 
of COX-2 and OPN expression, and presented as the fold change of flow over no flow control 
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(Fig. 2.3). Cells with cilia lengthened by fenoldopam were more responsive, exhibiting elevated 
mRNA expression of 124% ± 27% and 48% ± 8% of COX-2 and OPN respectively compared to 
unlengthened controls.  Lithium resulted in a more modest, but still significant increase in 
response of 61% ± 13% and 34% ± 8% for COX-2 and OPN. This flow-induced enhanced 
osteogenic response was observed in cells with elongated primary cilia, regardless of the means 
of lengthening, suggesting that the effect is due to lengthening and not an unanticipated effect of 
the agents utilized.  
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Figure 2.3: Cells with longer cilia are more mechanosensitive 
Cells were subjected to fluid flow for 1 hour, and the fold change of flow vs no flow control groups was compared. 
Cells expressed significant increases in COX-2 (A, B) and OPN (C, D) mRNA relative to GAPDH endogenous 
control when treated with either fenoldopam (A, C) or LiCl (B, D) for 16 hours. Mean ± SEM; n ≥ 5 for each group; 
*p < 0.05, **p < 0.01, ***p < 0.001. 
 
2.4.3. Recovery of cilia form and function 
We next sought to examine the potential of targeting primary cilia length to recover 
impaired cilia function. IFT88 inhibition was employed as a model of dysfunctional cilia, and 
has previously been used to mimic the effects of polycystic kidney disease 41. IFT88 is a critical 




Figure 2.4: Treatment with IFT88 siRNA disrupts cilia formation 
Overlays of primary cilia (green) and nuclei (blue) illustrate primary cilia incidence. Scramble control siRNA 
treatment for 48 hours does not disrupt primary cilia formation (A). IFT88 siRNA treatment results in decreased 
cilia length and incidence (B). Fenoldopam treatment recovers primary cilia formation in IFT88 siRNA treated cells 
(C). Scale bars = 10 µm. 
 
 
Cells treated with IFT88 siRNA displayed decreased primary cilia length and incidence 
compared to scramble control (Fig. 2.4A, B). IFT88 siRNA treated cells were then treated with 
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fenoldopam, and cilia length and incidence were noticeably recovered (Fig. 2.4C). Upon 
analysis, cilia of IFT88 siRNA treated cells were significantly shorter (Fig. 2.5A) and were 
present with lower incidence (Fig. 2.5C) than scramble control groups, with fenoldopam 
treatment significantly recovering cilia incidence. We then mechanically stimulated these cells to 
examine whether ciliogenesis recovery restored mechanosensitivity. Fluid flow was applied for 1 
hr and cells with impaired primary cilia formation displayed significantly decreased flow-
induced OPN mRNA expression by 43% ± 2%, compared to scramble control (Fig. 2.5B). 
Fenoldopam treatment was then able to recover this OPN response by 52% ± 1%, compared to 
IFT88 siRNA and vehicle treated cells. This further suggests that the length of primary cilia is 
critical to their function as a mechanosensor, and that as cilia formation was restored, so too was 
mechanosensitivity. We then confirmed that fenoldopam treatment of healthy, ciliated cells had 




Figure 2.5: Fenoldopam rescues ciliogenesis and mechanosensing 
Cells treated with IFT88 siRNA had decreased cilia length compared to scramble control, while fenoldopam 
treatment appears to recover cilia length (n ≥ 25 for scramble and fenoldopam treated, n = 15 for IFT88 siRNA 
alone) (A). Oscillatory fluid flow was applied to cells treated with IFT88 or Scramble control siRNA. Impaired cilia 
displayed a decreased OPN response to fluid flow, while fenoldopam treatment was able to recover flow stimulated 
OPN expression (B). Treatment with IFT88 siRNA decreases cilia incidence, but is recovered with fenoldopam 
treatment; n ≥ 8 fields of view (C). Fenoldopam treatment on untransfected cells has no effect on cilia incidence; n ≥ 
8 fields of view (D). Fenoldopam also does not alter IFT88 mRNA expression in untransfected cells (E). Mean ± 
SEM; n ≥ 4; ***p < 0.001. 
 
2.4.4. Fenoldopam increases cilia length through an AC6-cAMP mechanism 
Finally, we examined a potential molecular pathway through which fenoldopam increases 
primary cilia length. cAMP has been previously shown to be involved in ciliogenesis and 
primary cilia-mediated mechanotransduction, so we quantified adenylyl cyclase activity by 
measuring stimulated cAMP production 36,112. We increased primary cilia length by fenoldopam 
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treatment, and then briefly stimulated the cells with the adenylyl cyclase agonist, forskolin (Fig. 
2.6A). Fenoldopam treatment significantly enhanced the forskolin stimulated cAMP response by 
130% ± 25% compared to vehicle control. Additionally, fenoldopam treatment stimulated a 20% 
± 8% increase in AC6 mRNA expression (Fig. 2.6B). Because of the significant role of AC6 in 
primary cilia-mediated mechanotransduction, we used inhibition of AC6 as an alternative model 
of impaired cell mechanosensitivity. Treatment of osteocytes with AC6 siRNA resulted in a 
small but significant decrease in cilia length by 10% ± 3% (Fig. 2.6C), while AC6 inhibition had 
no effect on cilia incidence (Fig. 2.6D). Fenoldopam had no effect on recovering cilia length or 
incidence in AC6 siRNA treated cells. When cells with diminished AC6 were mechanically 
stimulated, AC6 knockdown cells displayed decreased AC6 and flow-induced OPN expression 
by 50% ± 3% and 30% ± 3% respectively, which was not recovered with fenoldopam treatment 





Figure 2.6: Fenoldopam enhances adenylyl cyclase production and activity 
Cells were treated with fenoldopam or vehicle control for 16 hours, and then forskolin stimulated for 20 minutes. 
Fenoldopam treatment significantly increased the cAMP response to forskolin stimulation (A). Fenoldopam 
treatment significantly increased AC6 mRNA expression (B). AC6 knockdown decreases cilia length, but is not 
recovered with fenoldopam treatment (C). Neither AC6 siRNA nor fenoldopam alter cilia incidence; n ≥ 8 fields of 
view (D). Oscillatory flow applied to AC6 siRNA treated cells elicits a decrease in AC6 and OPN mRNA 
expression, and is not recovered with fenoldopam treatment (E, F). Mean ± SEM; n ≥ 4 for each group; *p < 0.05, 
***p < 0.001. 
 
2.5. Discussion 
Our results demonstrate that primary cilia length plays a significant role in cell 
mechanosensitivity. We employed two distinct, clinically utilized, small molecules to increase 
cilia length, and both resulted in enhanced mechanosensitivity. Cells with impaired ciliogenesis 
have impaired mechanosensing, but this may be recovered with fenoldopam treatment. Finally, 
we show that fenoldopam modulates osteocyte mechanosensitivity through a mechanism 
involving AC6, and cells with diminished AC6 have shorter cilia and impaired mechanosensing. 
Based on clinical and biochemical considerations, fenoldopam was a more suitable 
candidate for further study than lithium, and thus was only used in studying the effects of IFT88 
and AC6 knockdowns. Fenoldopam is a dopamine D1-like receptor agonist clinically used as a 
vasodilator in cases of extreme hypertension 113,114. Lithium has a much less defined function and 
is clinically used to treat a wide range of mental disorders, including bipolar disorder 115. 
Furthermore, lithium is an inhibitor of GSK-3β and can have downstream effects on various 
signaling pathways including Wnt and Hedgehog. While lithium has been used to increase cilia 
length in a variety of cell types, other GSK-3β inhibitors have no effect on cilia length 116,117.  
Fenoldopam treatment increased cilia length, but also plays a role in adenylyl cyclase 
activity. The increase in forskolin stimulated adenylyl cyclase activity with fenoldopam 
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treatment implicates two potential mechanisms. First, it is possible that fenoldopam sensitizes 
adenylyl cyclases, resulting in an increased cAMP response to forskolin. Alternatively, 
fenoldopam may increase production of adenylyl cyclases, augmenting forskolin stimulated 
cAMP production. This second notion is consistent with previous work indicating that 
fenoldopam treatment upregulates AC6, a specific adenylyl cyclase isoform, production in 
kidney cells 118. Our results support this possible molecular pathway by demonstrating an 
increase in AC6 mRNA expression in response to fenoldopam stimulation. Previously, we have 
demonstrated that AC6 localizes to the osteocyte primary cilium and is critical for primary cilia-
mediated mechanotransduction 36. Besschetnova et al, reported that stimulating the cAMP 
signaling pathway results in increased cilia length 112. Using an siRNA mediated knockdown, 
they then showed that AC6 has a functional role in mediating primary cilia elongation. Together, 
these findings indicate that AC6-cAMP dynamics are critical to both primary cilia length and 
mechanotransduction, and that fenoldopam treatment stimulates this pathway. Furthermore, these 
results suggest that fenoldopam treatment enhances ciliary protein production to promote cilium 
elongation. 
Adenylyl cyclases and cAMP contribute to recovering and elongating primary cilia by 
stimulating IFT particle transport. It has previously been reported that stimulation of the adenylyl 
cyclase-cAMP-PKA signaling pathway augments anterograde transport of IFT particles to 
promote cilia elongation 112. Because fenoldopam enhances adenylyl cyclase production, this 
suggests that fenoldopam treatment is potentiating adenylyl cyclase activity and IFT particle 
transport. Our model of impaired cilia utilized an IFT88 knockdown, not a complete knockout of 
the gene, so it is possible that fenoldopam was able to enhance remaining IFT88 function and 
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promote cilia elongation and rescue cilia incidence. Furthermore, this presupposes that even 
though the IFT88 knockdown is satisfactory to impair cilia formation and function, sufficient 
IFT88 remains to elongate cilia. Our data show no change in IFT88 mRNA expression elicited 
by fenoldopam treatment suggesting that fenoldopam stimulated the remaining IFT88, rather 
than promoting production of new IFT88. This does not, however, discount the notion that 
fenoldopam treatment may instead prevent IFT88 knockdown driven disassembly of the cilium.  
The specific means by which cells with longer cilia are more mechanosensitive remains 
elusive, but there are two potential mechanisms of how this may occur. Schwartz et al, developed 
one of the first models of primary cilia deflection under fluid flow and hypothesized that longer 
cilia would experience greater membrane strain to increase opening of stretch-activated ion 
channels on the ciliary membrane 43. Alternatively, longer cilia may simply allow for the 
presence of more cilia-specific proteins and signaling molecules within this microdomain 119,120. 
Increasing the total amount of ciliary protein could enhance signal transduction within the ciliary 
compartment, modifying primary cilia-mediated mechanosensitivity. In fact, fenoldopam treated 
cells exposed to fluid flow have increased ciliary influx of calcium, which has been identified as 
one initiator of the mechanotransduction signaling cascade 39,42. It is also possible that cilium-
lengthening agents actually enhance ciliary protein production and trafficking to promote cilium 
elongation. 
The correlation between cilia length and critical ciliary proteins involved in 
mechanosensing was examined with AC6 siRNA treatment. This knockdown of AC6 decreased 
flow-induced osteogenic gene expression, yet fenoldopam treatment was not sufficient to rescue 
AC6 expression, or OPN expression as was demonstrated in the IFT88 knockdown model. 
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Because fenoldopam treatment was not able to recover AC6 or OPN mRNA expression in AC6 
knockdown cells, this may suggest that the ability of fenoldopam to enhance AC6 activity is 
critical to recovering cellular mechanosensing. However, AC6 knockdown also decreased 
primary cilia length, which was not recovered with fenoldopam, and did not alter cilia incidence. 
Altogether, these data suggest that both cilia length and protein production may be critical in 
primary cilia-mediated mechanosensing. 
Cells with longer cilia are more mechanosensitive, but primary cilia cannot be elongated 
indefinitely. Longer cilia are exposed to greater drag force, and are more likely to be sheared off 
57. For example, endothelial cell primary cilia are flow sensors in regions of low shear, 
specifically, because they are cleaved off as shear stresses increase 59. Interestingly, electron 
microscopy has shown that primary cilia structure is not constant along the ciliary axoneme and 
becomes increasingly disorganized and asymmetric at the distal tip 121,122. This loss of 
microtubule symmetry reduces the bending stiffness of the cilium at the distal end, making 
drastically elongated cilia more susceptible to removal by fluid shear 123.  
While osteocyte primary cilia are free-standing flow sensors in vitro, their 
mechanosensing function may differ in vivo. It has been estimated that the lacunar space in 
which osteocytes reside in vivo allows for only a 1 µm long cilium 100,101. Due to the spatial 
limitations within the lacuna, the potential effect of pharmacologically enhancing osteocyte cilia 
length in vivo is unclear. In fact, these spatial constraints may point to the cilium not being a 
free-flowing mechanosensor at all. Rather, osteocyte cilia may anchor to the lacunar wall, 
similarly to chondrocyte primary cilia which form integrin attachments with the surrounding 
extracellular matrix, ECM 63. A computational model by Vaughan et al, simulated osteocytes 
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exposed to fluid flow within the lacunar-canalicular network 92. The authors modeled a free-
standing cilium, 0.5 µm long, within a lacuna and calculated the resulting strain at the base of the 
cilium. Their model suggests that a cilium in this configuration does not experience a great 
enough strain to function as a flow sensor, but a cilium directly attached to the ECM does. The 
authors, however, do not account for the amount of membrane strain necessary to stimulate 
stretch-activated ion channels on the ciliary membrane, and may have overestimated the required 
strain for cilium stimulation. Fenoldopam treatment not only increases length, but may also 
enhance mechanosensitive protein levels, such as adenylyl cyclases and ion channels, within the 
cilium. Regardless of cilium length, this enriched protein trafficking to the cilium would increase 
chemical kinetics within the ciliary microdomain to modify cellular mechanosensitivity. 
Our results certainly suggest fenoldopam treatment, or similar agents which may increase 
cilia length, can be a potent method to enhance cell mechanosensitivity. However, the effect of 
fenoldopam on whole bone has not been examined, so the potential skeletal and systemic 
consequences in translating this work to in vivo models is still unknown. Statistical analysis of 
patients treated with various antidepressants, such as selective serotonin reuptake inhibitors 
which can block dopamine D2 receptors, revealed that these patients have increased risk of hip 
and femur fracture 124,125. Furthermore, many antidepressants and antipsychotics that block 
dopamine D2 receptors can cause decreased estrogen and testosterone levels leading to 
significantly reduced bone mass 126. All of these studies examine treatments which may affect 
dopamine D2 receptors, but at present there are no examinations of the impact of dopamine D1 
receptor agonists on bone formation. As such, no connection between fenoldopam treatment and 
skeletal health has been established. Because of this lack of direct evidence, such drugs have the 
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potential for a wide range of unknown side effects. Further work needs to be performed before 
any drugs altering dopamine signaling are used to treat bone disease.    
Targeting primary cilia-mediated mechanotransduction has widespread applications in 
preventative medicine that reach far beyond osteocytes. Numerous diseases are characterized by 
impaired primary cilia function. Mutations of PC2, polycystin 2, are attributed to polycystic 
kidney disease and skeletal deformations. Bardet-Biedl syndrome is characterized by 
malfunctioning BBS proteins at the base of the primary cilium, causing retinopathy, polydactyly, 
and renal failure 84,127,128. Recently, primary cilia have even been implicated in tumor 
development. Primary cilia help regulate Wnt signaling, changes in which have been correlated 
with cancer cell progression 129. Furthermore, some cancer cell types lose their primary cilia, 
which potentially contributes to their insensitivity to repressive signals 130. Additionally, 
atherosclerotic plaques form in areas of low and disturbed arterial fluid flow, regions that 
interestingly have an increased incidence of primary cilia.  This suggests that these cells are 
compensating, increasing their sensitivity to low fluid flow in order to promote an adequate 
cellular response 59,131. Within bone, osteocytes utilize primary cilia to sense and respond to 
mechanical cues. In vitro and in vivo studies demonstrate that when these cilia are removed there 
is a decreased bone formation response to loading 36,82,83.  Fenoldopam is already an FDA 
approved drug, and our results point to it being an attractive candidate for study in numerous in 
vitro and in vivo applications to treat such a myriad of conditions. 
We have demonstrated that cells with longer primary cilia are more mechanosensitive, 
and we present a simple, yet robust, method to enhance primary cilia-mediated 
mechanotransduction. Fenoldopam treatment not only increased primary cilia length, protein 
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production, and mechanosensitivity, but also rescued cilia form and function in cells with 
impaired cilia. Although fenoldopam and lithium are likely not ideal treatments for all cilia-
related conditions, the strategy of modulating primary cilia sensitivity may aid in combating the 
phenotypes displayed by various ciliopathies, maintain sensitivity of cancer cells so that they 
respond to repressive signals, cue cellular responses to slow atherosclerotic plaque formation, 





3. High-throughput drug screening allows identification of 
ciliogenesis modifying compounds 
3.1. Abstract 
In Chapter 2 we identify two small molecules, fenoldopam and lithium, as compounds 
that increase primary cilia length. Furthermore, we find the cells with longer cilia are more 
mechanosensitive. Primary cilia play a critical role in mechanosensing, chemosensing, and signal 
transduction in a myriad of cell types. Moreover, numerous different human conditions are being 
attributed to aberrant ciliogenesis. Disrupted ciliogenesis can result in improper embryogenesis, 
skeletal patterning disorders, polycystic kidney disease, anosmia, and retinitis pigmentosa, 
among numerous other conditions. While we have identified fenoldopam as a compound with 
potential to be repurposed for bone applications, our list of candidate therapeutics to treat such a 
range of ciliopathies is limited. In this chapter we utilize high-throughput drug screening to 
recognize compounds that manipulate ciliogenesis. This work allows us to identify individual 
small molecules, as well as classify compounds based on mechanism of action to help inform the 




As previously discussed, primary cilia are solitary immotile organelles serving chemo 
and mechanosensing roles in numerous different cell types. Primary cilia are comprised of 
microtubule doublets that are highly acetylated 132. Furthermore, primary cilia form a unique 
microdomain within the cell to which particular proteins localize, and through which many 
signaling pathways are transduced. Impaired primary cilia formation is being implicated with an 
increasing number of different health conditions being termed ciliopathies. The most notable of 
these being disrupted embryonic patterning and polycystic kidney disease 31. Primary cilia also 
serve chemosensing roles in olfaction as well as in neurons and in the retina controlling vision 
133. 
Due to the acetylated microtubule composition of the ciliary axoneme, it is anticipated 
that compounds targeting microtubule stability and microtubule acetylation, as well as cell cycle 
progression, will significantly impact ciliogenesis. Primary cilia formation is tightly regulated 
with the cell cycle, with ciliogenesis occurring during the G1 phase of the cell cycle 134. As cells 
approach the G2 and S phase the cilium is disassembled before cell division. Taxol, and its 
derivatives, stabilize microtubules to prevent them from depolymerization, and can also arrest 
cells in the G1 phase, when ciliogenesis occurs 135. Histone deacetylases (HDACs) increase α-
tubulin acetylation to also stabilize microtubules 136. 
Primary cilia formation can be altered, pharmacologically, having a direct impact on cell 
function. Besschetnova et al. demonstrated that inhibiting intracellular calcium or stimulating the 
cAMP-PKA signaling pathway can significantly enhance primary cilia length 112. Recently it has 
been demonstrated that increasing primary cilia length with fenoldopam can potentiate 
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mechanosensing in endothelial cells and osteocytes, resulting in enhanced nitric oxide production 
to reduce blood pressure, and increased osteogenic signaling, respectively 56,137. These works 
demonstrate that ciliogenesis can be pharmacologically enhanced, having a direct impact on cell 
function. 
Targeting primary cilia is a potent way to manipulate cell activity, such as by sensitizing 
cells to chemical or mechanical stimuli. This has implications in combating diseases ranging 
from osteoporosis, atherosclerosis, and polycystic kidney disease, to cancer and primary ciliary 
dyskinesia. While several compounds are known to manipulate cilia length, the list is minimal. 
Here, we utilize high-throughput drug screening to expand our library of candidate bioactive 
small molecules that increase primary cilia length, to both further our understanding of cilia 
biology and identify potential disease treating compounds. 
 
3.3. Materials and Methods 
3.3.1. Summary 
In this chapter we perform high-throughput drug screening to expand our list of candidate 
compounds that increase primary cilia length. We established a high-throughput screening 
system in collaboration Dr. Charles Karan and his team at the High-Throughput Screening 
Center at the Columbia Genome Center. This platform involves an automated process of cell 
culture on 384-well plates, drug treatment with 6931 compounds, staining, imaging, and image 
analysis.  
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3.3.2. Cell culture 
MLO-Y4 osteocytes were maintained on collagen I-coated dishes in MEMα (Life 
Technologies) supplemented with 5% fetal bovine serum (FBS), 5% calf serum (CS), and 1% 
penicillin/streptomycin (P/S) at 37°C and 5% CO2. Osteocytes were then seeded onto 384-well 
collagen-coated plates for 72 hours before fixation. Cells were treated, in triplicate, with 6931 
biologically active small molecules from a collection of libraries for 16 hours before fixation. 
These libraries include Tocris, Sigma LOPAC, Selleck Chemical, Prestwick, and Spectrum 
commercially available compound libraries. All cell seeding and plate handling was performed 
with the Perkin Elmer cell::explorer workstation. 
3.3.3. High-throughput imaging 
Cells were fixed in 4% paraformaldehyde and permeabilized with 0.1% Triton-X 100 
(Sigma). 10% goat serum (vendor) was used for blocking. Cilia were stained using a monoclonal 
antibody against acetylated α-tubulin (1:20) from a C3B9 hybridoma cell line, and visualized 
with AF488 (1:1000, ThermoFisher). Nuclei were visualized with Hoechst. Cells were imaged 
using a GE INCell 2000 high-throughput imager at 40X magnification. 4 fields of view were 
taken per well.  
3.3.4. Automated cilia detection and measurement 
Each pair of nuclei and cilia images was first analyzed individually, then the entire 
population was examined to evaluate each compound’s effect on cilia length and incidence. A 
custom MATLAB script was developed to perform all image analysis. This script first utilizes an 
enhanced implementation of a watershed transform, which is a segmentation tool which enables 
detection of similarly shaped overlapping particles in noisy images by the procedural whittling 
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down of pixels found close to the edge of such particles. Our augmentation of the algorithm 
incorporates thresholding for noise removal based on signal intensity and object size, nuclei 
dilation to exclude non-cellular artifacts, as well as skeletonization of cilia to quantify length. 
The results of the analysis are number of nuclei, number of cilia, and average cilia length in each 
image. 
3.3.5. Identification and classification of hits 
Compounds were selected based on deviation from the population mean. Each well was 
normalized to vehicle control images on each plate, allowing the establishment of a normalized 
population mean. Hits were chosen based on compounds whose triplicate mean was furthest 
(based on standard deviation away) from the population mean. This was performed to identify 
the 105 individual compounds with the greatest deviation in terms of increased cilia length, and 
can also be performed for changes in cilia incidence. Compounds were classified based on 
mechanism of action. 
 
3.4. Results 
3.4.1. High-throughput screening platform 
To identify compounds that modulate primary cilia formation we developed a high-
throughput platform to automate cell culture, staining, imaging, and analysis, Fig. 3.1. This 
platform was used to examine the effects of 6931 small molecule treatments on osteocyte 
primary cilia length and incidence. Osteocytes were chosen as the model cell type, as we have 
repeatedly demonstrated that they form primary cilia of consistent length and incidence 35,137,138. 
Cells were cultured on 384-well plates, and treated with small molecules with known biologic 
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activity, enabling classification of mechanisms of action. Drug treatment was applied for 16 
hours at 10 µM concentration, performed in triplicate, before fixation and immunostaining of 
primary cilia. Cells were then imaged using the GE INCell 2000 High Content Analyzer, 
capturing 4 fields of view per well at 40X magnification. Additionally, each plate contains 8 
wells of DMSO vehicle control. 
 
 
Figure 3.1: High-throughput screening platform 
An automated platform was developed to perform the complete high-throughput drug screening and analysis. First, 
cells are seeded on 384-well plates, then treated with one of 6931 compounds with known biologic activity from 
commercially available small molecule libraries. Cells are then fixed, stained, and imaged. Images are then analyzed 




3.4.2. Primary cilia detection and analysis 
A MATLB script was developed to detect and analyze changes in ciliogenesis, Fig. 3.2. 
Nuclei and cilia images were binarized based on object size and signal intensity. A dilated mask 
was overlaid on the nuclei to identify only cilia that are associated with a nucleus, removing 
image artifacts. Cilia were skeletonized to quantify cilia length. Primary cilia incidence was 
quantified as the number of cilia versus nuclei per field of view. 
Cilia length and incidence for each field of view were normalized to vehicle control on 
that individual plate. This allowed development of a normalized population average and standard 
deviation. Initially, hits were chosen as compounds with a normalized average 1.5 standard 
deviation above the population average 139. To control for toxic effects only small molecules 
with at least 40% viability, based on number of nuclei versus control, were selected as hits. 
Furthermore, compounds repeated between multiple libraries eliciting the same effect on cilia 
length or incidence were excluded, such that only one of the repeated compounds was selected as 
a hit. For example, bufexamac was present in 3 libraries and was listed as a hit increasing length 
from each library, but is only counted once for analysis of mechanism of action. This resulted in 
103 individual compounds that increase primary cilia length, independent of changes in cilia 
incidence, and 92 compounds that increase cilia incidence independent of length. 18 individual 




Figure 3.2: Primary cilia imaging, detection, and analysis 
Cells stained for primary cilia (acetylated α-tubulin; visualized with AF488, green) and nuclei (Hoescht, blue), and 
imaged at 40x magnification. A representative image (A) is cropped to better display features, scale bar represents 
30 µm. A custom MATLAB script identifies nuclei and cilia for analysis (B). The script detects nuclei (blue), and 
applies a dilation mask to reject objects not associated with a cell (white). Objects are further filtered based on size 
and signal intensity. Rejected objects are labeled in (red) and identified cilia are labeled in (green). Cilia length and 
incidence distributions are displayed as histograms of compound standard deviations from population mean (C, D). 
 
3.4.3. Compound classification 
Compounds were classified based on mechanism of action to assess pathways through 
which primary ciliogenesis is altered, Fig. 3.3, 3.4. The most common class of compounds was 
DNA/RNA synthesis inhibitors; including anti-folates, topoisomerase inhibitors, 
purine/pyrimidine (nucleoside) analogs, and general DNA/RNA synthesis inhibitors not falling 




agonists increase length, as well as an adenylyl cyclase activator. As previously discussed, it has 
been demonstrated that DR1 agonists enhance adenylyl cyclase production. Additionally, 
compounds affecting microtubule stability, as well as GSK3 and HDAC inhibitors also increase 
primary cilia length. Of the 103 hits increasing length, 37 did not share a distinct pathway with 
another compound. 7 of these compounds have biologic activity, but their mechanisms of action 
have not been explicitly described in mammalian cells. These compounds comprise 
phytochemicals and flavonoids. 30 of 92 total incidence hits were also individual compounds. 
All hits increasing both cilia length and incidence are listed in Table 3.1, along with the standard 
deviation away from the population average. Compounds that are conserved between these lists 
are highlighted. These conserved hits are categorized by mechanism of action in Fig. 3.5. 
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Figure 3.3: Classification of compounds that increase cilia length 
Compounds that increase cilia length were classified based on mechanism of action, independent of cilia incidence. 
Only classes with at least 2 hits are listed here to demonstrate repeated mechanisms of action increasing cilia length. 
Classes marked with dots (anti-folates, general DNA/RNA synthesis inhibitors, topoisomerase inhibitors, and 
nucleoside analogues) all represent different compounds that inhibit DNA and RNA synthesis, slowing proliferation. 
Classes marked with slashes (DR1 agonists, Adenylyl cyclase modulators) represent compounds that increase AC 
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Figure 3.4: Classification of compounds that increase cilia incidence 
Compounds that increase cilia incidence (independent of changes in cilia length) were classified based on 
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Compounds increasing: 
Cilia length                                                              Cilia incidence 
Drug Name 
Average 












Acetanilide (Antifebrin) 1.696295 




2 4 -DIHYDROXYCHALCONE 4 
-GLUCOSIDE 1.598346 
 
Amfebutamone (Bupropion) 1.605458 
2-Methoxyestradiol 1.619623 
 
Aminophylline ethylenediamine 2.589753 
5-BDBD 1.92035 
 
Amiodarone HCl 3.380494 
5-fluorouracil 1.775485 
 
Arcyriaflavin A 1.891508 






AG 494 1.57514 
 
Avobenzone (Parsol 1789) 1.501535 
AM 630 1.74067 
 
Azasetron HCl 1.652885 
Amethopterin (RS) 2.927481 
 
Benidipine hydrochloride 1.811129 
AMINOPTERIN 2.587185 
 
Betaxolol hydrochloride (Betoptic) 1.630679 
BAY 61-3606 hydrochloride 
hydrate 1.540018 
 
Bethanechol chloride 1.763703 














Bromhexine HCl 1.547211 
 




BW 373U86 1.553484 
 
Cleviprex (Clevidipine) 1.837172 
CP 339818 hydrochloride 1.714638 
 
CPT 11 1.633435 
CPT 11 1.893689 
 
Detomidine HCl 1.92214 
CY 208-243 2.56706 
 
Dexmedetomidine HCl (Precedex) 2.924328 
CYCLOHEXIMIDE 3.609172 
 
Dextrose (D-glucose) 1.517602 





Diphenhydramine HCl (Benadryl) 1.928039 
DEGUELIN(-) 2.480167 
 
Dipyridamole (Persantine) 2.055435 





Edaravone (MCI-186) 1.536994 
DEOXYKHIVORIN 1.681439 
 
Fenofibrate (Tricor Trilipix) 2.949682 
DEOXYSAPPANONE B 73 -
DIMETHYL ETHER ACETATE 3.162781 
 





Diphenyleneiodonium chloride 2.60257 
 
Flutamide (Eulexin) 2.034848 
Docetaxel 3.416309 
 
Gabexate mesylate 1.870428 







DUARTIN DIMETHYL ETHER 2.069704 
 
Hydroxyurea (Cytodrox) 1.987889 
ESTRADIOL CYPIONATE 1.559704 
 
Idoxuridin 1.798224 
Ethacridine lactate monohydrate 2.114111 
 
Iloperidone (Fanapt) 1.774571 






Ginkgolide B 1.581395 
 
Isoprenaline hydrochloride 1.622508 
GW 1929 1.650101 
 





HECOGENIN ACETATE 2.209553 
 
Levosimendan 1.520002 





Lomustine (CeeNU) 2.227746 
IC 261 1.651397 
 
LY 364947 1.590856 
Indirubin-3'-oxime 2.474718 
 






Metoprolol tartrate 1.601192 
Kenpaullone 3.279991 
 
Metronidazole (Flagyl) 2.09186 
KHIVORIN 1.722962 
 




Mycophenolate mofetil (CellCept) 1.654129 
Lonidamine 2.357239 
 
Nefiracetam (Translon) 1.552041 
Loratidine 2.260501 
 






NXY 059 1.838152 
Methotrexate 3.09706 
 




Ondansetron (Zofran) 1.506065 
MONENSIN SODIUM (monensin 






Mycophenolate mofetil (CellCept) 1.579155 
 
Ozagrel HCl 1.683075 
Oxfendazole 1.573848 
 
Pefloxacin mesylate 1.681721 
PARAROSANILINE PAMOATE 2.388812 
 
Pemetrexed 2.082984 
PD 169316 3.454305 
 
Phenindione (Rectadione) 1.687887 
PD-407824 1.510015 
 




PERILLIC ACID (-) 2.196372 
 
Proparacaine HCl 1.522795 
PHA 767491 hydrochloride 1.724284 
 
Propylthiouracil 1.658653 





Ranolazine (Ranexa) 1.564839 
Pralatrexate(Folotyn) 2.105394 
 
Rivastigmine tartrate (Exelon) 1.663812 
PYRIMETHAMINE 3.194135 
 
Rosuvastatin calcium (Crestor) 1.643692 
PYRVINIUM PAMOATE 2.834048 
 
S(-)-Atenolol 2.17694 
QUINIDINE GLUCONATE 1.82481 
 
SB 239063 1.794902 
QUININE SULFATE 1.801811 
 
Sodium butyrate 2.3981 
RESERPINE 1.972238 
 
Sorafenib (Nexavar) 1.677517 
Retinoic acid p-hydroxyanilide 2.487406 
 
Sulfamethoxazole 1.766832 
Ro 19-4605 1.584464 
 
TAME 2.32474 
S 14506 hydrochloride 1.53968 
 




Temocapril HCl 1.876515 
SANT-1 1.811052 
 
Tiotropium Bromide hydrate 1.593179 
SB 203580 1.796593 
 
Tolnaftate 1.5099 
SB 206553 hydrochloride 1.703544 
 
Topotecan hydrochloride hydrate 2.750407 
SB 228357 2.332256 
 
Tranexamic acid (Transamin) 1.58212 
SB 239063 4.000291 
 
Trifluridine (Viroptic) 2.117341 
SB 408124 2.398154 
 
Tropisetron 1.694477 
SB 415286 2.049715 
 




SKF 77434 hydrobromide 1.527282 
 
Zolmitriptan (Zomig) 1.520897 
SKF 86002 dihydrochloride 1.549216 
   Sorafenib (Nexavar) 1.499834 
   THIOGUANINE 1.674629 
   
Topotecan hydrochloride hydrate 3.898638 
   Triamterene 2.775097 
   Trifluridine (Viroptic) 1.772731 
   TULOBUTEROL 2.059746 
   
Tyrphostin B44 (-) enantiomer 1.877017 
   Vinblastine 1.771483 
   Vorinostat 3.282859 
   VU 0155069 1.618479 
    
Table 3.1: List of hits increasing cilia length and incidence 
All compounds determined as hits based on statistical analysis of 1.5 standard deviations away from population 
mean. Lists comprise hits that increase cilia length independent of incidence, and incidence independent of length. 
Standard deviations away are listed, with compounds increasing length on the left, and compounds increasing 





Figure 3.5: Conserved classes of compounds 
Compounds conserved between lists of hits independently increasing cilia length and incidence are classified based 
on mechanism of action. Below each class is also listed the number of conserved compounds in each group, 18 in 
total. Anti-folates (DHFR inhibitors) are the most commonly conserved, with topoisomerase, HDAC, and 
DNA/RNA synthesis inhibitors all having multiple conserved hits. 
 
3.5. Discussion 
Using our high-throughput drug screening platform, we identify unique compounds and 
classes of compounds that enhance ciliogenesis. This has potential to elucidate molecular 
pathways and targets for therapeutic development of compounds to treat conditions marked by 
impaired ciliogenesis. Impaired cilia formation has consequences in cell signaling and 
homeostasis, as well as chemo and mechanosensing. 
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The final list of hits is comprised only of individual compounds, yet many compounds 
were repeated in different libraries with the same mechanism of action. This screen utilizes 
multiple different commercially available libraries, so there is overlap in compounds between 
libraries. Because of this, many compounds identified by the 1.5 standard deviation threshold are 
repeated, with 17 of the 103 compounds increasing cilia length having at least one repetition in 
another library. For example, both bufexamac and methotrexate are listed as hits from Selleck 
and Prestwick libraries. 92 compounds were identified to increase cilia incidence (independent of 
cilia length), with 8 of these containing library repetitions with similar effects on incidence. 
Compound repetition between libraries demonstrates robustness of the entire drug treatment, 
imaging, and analysis platform. 
The results from the screen focus on compounds that increase primary cilia length and 
incidence. We also analyzed the screening data for compounds that decrease cilia length and 
incidence. This, however, elicited almost no hits. Compounds that decreased cilia length or 
incidence by at least 1.5 standard deviations also caused cell death. Of compounds that decreased 
cilia incidence, none retained at least 40% cell viability. Many of the ciliopathies that we 
described earlier in this thesis are characterized by impaired cilia formation and function. 
Because of this, we focused the analysis of our drug screen results on compounds that increase 
cilia length and incidence. 
Our high-throughput screening platform does not necessarily exclude compounds not 
listed as hits. Through this platform we only tested compounds at 10 µM concentrations over a 
16 hour timeframe. Lithium was not classified as a hit, however we have previously 
demonstrated that lithium increases cilia length over 16 hours, at 500 µM concentration 137. Cilia 
 55 
length changes have also been reported with 3 hours of drug treatment with calcium channel 
blockers (gadolinium, 30 µM) or adenylyl cyclase activators (forskolin, 100 µM) 112. While a full 
dose-response on this complete bioactive library of 6931 compounds was not feasible, 
classifying compounds based on mechanism of action still allows examination of pathways 
through which ciliogenesis may be modified. 
The largest group of hits that increase cilia length are DNA and RNA synthesis 
inhibitors, including anti-folates, topoisomerase inhibitors, purine/pyrimidine analogues, and 
other less specific DNA/RNA inhibitors. As previously introduced, ciliogenesis coincides with 
the cell cycle, and deciliation occurs with the initiation of DNA synthesis 140. Additionally, 
topoisomerase inhibitors have also previously been demonstrated to enhance ciliogenesis 141. 
Purine and pyrimidine analogues additionally prevent the continuation of the cell cycle, allowing 
enhanced ciliogenesis 142. The role of anti-folates and dihydrofolate reductase inhibitors 
(DHFRs) on primary cilia formation has not been explicitly examined, but because DHFR 
inhibitors impair DNA/RNA synthesis, this result is not unexpected 143. In fact, certain doses of 
prenatal exposure to the DHFR inhibitor methotrexate can result in methotrexate embryopathy, 
characterized by altered patterning and embryogenesis, consistent with altered primary cilia 
function 144.  
Drug classification also supports a purported dopamine receptor–adenylyl cyclase–
calcium – related pathway to enhance cilia length. Several distinct compounds that act as 
agonists of dopamine D1-like receptors (DR1), as well as compounds that stimulate adenylyl 
cyclase activity, are demonstrated as hits in our screen. It has previously been demonstrated that 
fenoldopam, a DR1 agonist enhances cilia length 56,137. Furthermore, it has been demonstrated 
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that DR1 agonists enhance AC6 production, which results in increased cAMP production 118. 
Besschetnova et al. previously reported that blocking calcium channels or stimulating cAMP 
production and PKA activation all increase primary cilia length, in a process that is impaired 
with AC6 disruption 112. AC6 is a calcium inhibited isoform of adenylyl cyclase that localizes to 
the primary cilium 36. Through our screen we also identify general calcium channel blockers that 
increase cilia length. Together with existing literature, the compounds classified through our 
screen help to demonstrate a pathway through which DR1 agonists stimulate an increase in AC6 
production to promote cilia elongation. Previously we have also demonstrated that AC6 plays a 
critical role in load-induced bone formation and mechanotransduction 36,86. Our results 
demonstrate that DR1 and AC agonists have potential use in promoting bone formation for the 
treatment of bone diseases such as osteoporosis. 
Histone deacetylases have been implicated in cilia formation, and suggest a length-
stiffness functional relationship. It has been previously demonstrated that HDACs, including 
HDAC2 and HDAC6, activity results in cilia disassembly 145,146. Primary cilia contain heavily 
acetylated microtubules, and this acetylation stabilizes microtubules from disassembly 136. 
HDAC6 inhibition also stabilizes cilia to prevent mechanically-induced disassembly 147. We 
have demonstrated that increased cilia length enhances mechanosensitivity; however, we have 
also shown that increased microtubule acetylation by HDAC6 inhibition increases primary cilia 
stiffness to abrogate primary cilia-mediated mechanotransduction 132,137. This distinction 
suggests that a relationship exists whereby both cilia length and stiffness can independently 
impact its function as a cellular mechanosensor. 
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Our drug screening platform utilized osteocytes as a model system, but modulating 
primary ciliogenesis has broad implications in treating numerous human conditions. Increasing 
cilia length can enhance cell mechanosensitivity. In the context of bone augments osteogenic 
activity and may have potential as a bone disease therapeutic strategy 137. Increasing cilia length 
also has implications in treating hypertension resulting from disrupted cilia mechanosensing 56. 
Modulating ciliogenesis can also restore chemosensing. A mouse model of diminished IFT88 
production leads to impaired cilia formation, resulting in disrupted olfaction 133. When 
ciliogenesis is recovered – using an adenovirus to promote IFT88 expression – olfaction in the 
mice is restored. Primary ciliogenesis has also been linked to tumor progression, with many 
cancer types reported to lose primary cilia 70. In particular, premalignant and invasive breast 
cancer cells both display significantly fewer cilia than normal breast tissue 75. Primary cilia 
regulate hedgehog signaling, which is known to be disrupted in tumorigenesis 70. Thus, restoring 
ciliogenesis also has significant potential in slowing cancer progression. Understanding 
ciliogenesis and identifying modulators of this process are critical to developing therapeutic 




4. Osteocyte cilia mediate paracrine signaling between 
cells within bone 
4.1. Abstract 
Bone maintenance and mechanotransduction is regulated by intercellular communication 
between the cells within bone. Osteocytes residing deep within bone tissue have been 
demonstrated to be highly mechanosensitive, and it is believed that these cells coordinate 
intercellular signaling to direct bone formation and osteogenic differentiation. As demonstrated 
in Chapter 2 of this thesis, primary cilia are critical osteocyte mechanosensors. In this chapter we 
mechanically stimulate osteocytes and use the conditioned media to culture bone-forming 
osteoblasts and mesenchymal stem cells (MSCs), to study mechanically-induced intercellular 
paracrine signaling. We demonstrate that the osteocyte cilium, and ciliary mechanosensing 
proteins, play a critical role in initiating the mechanotransduction events that result in pro-
osteogenic paracrine signaling to osteoblasts. Furthermore, we demonstrate that enhancing 
osteocyte primary cilia-mediated mechanotransduction with fenoldopam augments osteoblast 
activity and MSC osteogenic differentiation. Together, this demonstrates a regulation of 




The function of osteocytes was long unknown, since osteoblasts actively form new bone 
material and mesenchymal stem cells can differentiate into osteoblasts, while osteocytes resorb 
bone. Osteocytes reside deep within the lacuno-canalicular network in bone, comprising over 
90% of all bone cells 148. Studies now suggest that this dominant cell type actually serves a 
mechanosensing role in bone; and moreover, that osteocytes direct signaling to other cells within 
bone. Notably, Tatsumi et al. utilized an in vivo osteocyte-specific ablation model and found 
impaired bone mechanotransduction in mice lacking osteocytes 81.  
The prevailing paradigm is that osteocytes sense mechanical forces, and transduce these 
signals to direct the activity of the other cell types within bone. It is believed that osteocytes 
signal to osteoblasts, osteoclasts, and MSCs through soluble paracrine signals as well as direct 
cell communication. However, only recently has this phenomena been explicitly demonstrated 
149,150. Osteocytes subjected to pulsatile fluid flow were found to secrete soluble factors into the 
media that increase osteoblast proliferation, potentially through activation of a nitric oxide 
pathway 149. More recently, it was found that osteocytes exposed to oscillatory fluid flow display 
enhanced signaling to MSCs, increasing MSC osteogenic differentiation, migration, and 
proliferation 150,151. Moreover, our group also recently demonstrated that paracrine factors 
secreted by mechanically stimulated osteocytes can elicit epigenetic changes in MSCs that 
promote osteogenic differentiation 152. 
While we previously described that primary cilia play a significant role in osteocyte 
mechanosensing, it is unclear how this initial mechanotransduction event may be transduced into 
downstream signaling to other cell types. As mentioned earlier in this thesis, impairing primary 
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cilia formation disrupts osteocyte mechanosensing, and whole bone mechanotransduction. 
Similarly, knockdown and knockout of ciliary proteins such as stretch-activated ion channels 
(TRPV4, PC2) and mechanotransductive proteins (AC6) abrogates osteocyte and whole bone 
mechanosensing. Furthermore, we previously demonstrated that we can pharmacologically 
sensitize the osteocyte cilium to mechanical stimulation. It is unclear, however, how these 
proteins or manipulation of the osteocyte cilium impact the intercellular bone signaling axis. 
 
 
Figure 4.1: Flow-induced osteogenic paracrine signaling 
A prevailing paradigm in bone mechanotransduction is that osteocytes sense mechanical stimuli and transduce these 
signals to direct osteoblast-mediated bone formation and mesenchymal stem cell osteogenic differentiation. In this 




To study intercellular paracrine signaling, we collect conditioned media from 
mechanically stimulated osteocytes and use it to culture osteoblasts and MSCs. This model 
allows RNA and pharmacologic manipulation of cilia and ciliary proteins specifically in 
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osteocytes, while quantifying resultant osteogenic changes in osteoblasts and MSCs. To study 
soluble paracrine signaling from mechanically stimulated cells we utilized a rocking platform to 
supply oscillatory fluid flow and consistently collect conditioned media. Based on the size of the 
culture vessel, amount of media, placement on rocker, and rocking angle and frequency, the peak 
shear stress can accurately be calculated 153. Using this scheme we can study not only the initial 
ciliary mechanosensing events, but how the resultant downstream signaling impacts intercellular 
communication. 
4.3.2. Cell culture 
As performed in Chapter 2, MLO-Y4 osteocytes were cultured on collagen I-coated 
dishes in MEMα (Life Technologies) supplemented with 5% FBS, 5% CS, and 1% P/S at 37°C 
and 5% CO2. Osteocytes were seeded at 2800 cells/cm2 for 72 hours before application of fluid 
flow. MC3T3 osteoblasts were cultured in MEMα supplemented with 10% FBS and 1% P/S. 
Osteoblasts were seeded at 2000 cells/cm2 72 hours before receiving conditioned media. 
C3H10T1/2 MSCs were cultured in DMEM low glucose (Life Technologies) supplemented with 
10% FBS and 1% P/S, and seeded at 1100 cells/cm2 72 hours before culture with conditioned 
media 150. Osteocytes were treated with 10 µM fenoldopam mesylate (Sigma) for 16 hours or 5 
µM tubastatin (Sigma) for 3 hours, prior to experimentation.   
4.3.3. Mechanical stimulation 
Osteocytes were cultured on rectangular flasks (8.2 x 9.2 cm; 12.5 ml of media) on a 
rocking platform which oscillated at a frequency of 0.33 Hz with an amplitude of 1.3 cm, 
supplying 0.08 Pa shear stress for 2, 6, 12, or 24 hours, Fig. 4.2. Shear stress generated by 
oscillatory fluid flow was calculated as previously performed 153. 12 hours of fluid flow was used 
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in all experiments. Cells were also cultured in static conditions as a no flow control. Conditioned 
media was collected from osteocytes immediately upon completion of rocking, and used to 
culture osteoblasts or MSCs for 24 or 48 hours, respectively. 
 
 
Figure 4.2: Model of flow-induced paracrine signaling 
To study mechanically-induced osteogenic paracrine signaling between osteocytes and osteoblasts/MSCs, we 
utilized a rocker platform to perform conditioned media studies. In this platform, MLO-Y4 osteocytes are placed on 
a rocker to apply oscillatory fluid flow mechanical stimulation. The conditioned media is then collected and used to 
culture MC3T3 osteoblasts and C3H10T1/2 mesenchymal stem cells. With this set-up we can then manipulate 
osteocyte primary cilia-mediated mechanotransduction (such as by siRNA-mediated knockdown or pharmacologic 
challenge) and study the resulting changes in paracrine signaling leading to altered osteoblast and MSC activity. All 
results are compared relative to static (no flow) osteocytes. 
 
4.3.4. RNA interference in osteocytes 
Gene silencing was performed only in osteocytes, 48 hours prior to application of fluid 
flow, by siRNA-mediated knockdown, as described in Chapter 2. All data was compared to 
scramble siRNA control. Primary cilia were disrupted by IFT88 siRNA (5′- 
CCAGAAACAGATGAGGACGACCTTT -3’) 137. Adcy6 (5’- CCTGCCACCTACAAC-
AGCTCAATTA -3’), Pkd2 (5’- CCTCTTGGCAGTTTCAGCCTGTAAA -3’), and TRPV4 (5’- 
GATGGACTGCTCTCCTTCTTGTTGA -3’) were disrupted as previously performed 35,137. 
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4.3.5. mRNA expression 
RNA isolation and qRT-PCR was performed as described in Chapter 2. Osteoblasts and 
MSCs were washed with PBS and total mRNA was isolated using TriReagent (Sigma), 
immediately following 24 hours (48 hours for MSCs) of culture in conditioned media from 
mechanically stimulated (or static control) osteocytes. Total mRNA was converted to cDNA by 
TaqMan reverse transcriptase (Applied Biosystems). Gene expression was analyzed by 
quantitative real-time PCR using primers and probes (Life Technologies) for analysis of 
osteopontin, OPN (Mm00436767_m1), osterix, OSX (Mm04209856_m1), and GAPDH 
(4351309). Samples and standards were run in triplicate, and all gene expression was normalized 
to GAPDH endogenous control. 
4.3.6. Analysis 
All data were analyzed with one-way ANOVA followed by Bonferroni post-hoc 
correction. Values are reported as mean ± SEM, with p < 0.05 considered statistically significant. 
Sample size, n, represents biological replicates. 
 
4.4. Results 
4.4.1. Increased duration of flow enhances signaling to osteoblasts 
Cultured osteocytes were placed on the rocker platform and subjected to oscillatory fluid 
flow for 2, 6, 12, or 24 hours, each timepoint with a corresponding static control. Media was 
collected and used to culture osteoblasts for 24 hours. At each timepoint osteoblasts 
demonstrated a significant increase in osteopontin (OPN) mRNA expression compared to static 




Figure 4.3: Osteoblast response to increasing durations of osteocyte mechanical stimulation 
Osteocytes were exposed to oscillatory fluid flow (F), or no flow control (NF), for 2, 6, 12, and 24 hours. 
Conditioned media was collected from osteocytes and used to culture static osteoblasts for 24 hours. Osteoblasts 
were then immediately lysed for mRNA expression of osteopontin. At each timepoint osteoblasts expressed 
significantly more osteopontin mRNA relative to no flow control of the respective timepoint. Mean ± SEM; n ≥ 4 
for each group; ***p < 0.001. 
 
4.4.2. Intercellular signaling is impaired with cilia/associated protein disruption 
We next sought to examine the role of osteocyte primary cilia-mediated 
mechanotransduction on osteogenic intercellular paracrine signaling. Primary cilia formation was 
disrupted using siRNA-mediated knockdown of IFT88, while mechanotransduction proteins 
were impaired by knockdown of the ciliary stretch-activated ion channels TRPV4 and PC2, or 
knockdown of AC6. Knockdown of osteocyte cilia or ciliary mechanosensing proteins 
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Figure 4.4: Osteocyte primary cilia direct osteogenic paracrine signaling 
Osteocyte primary cilia-mediated mechanotransduction was disrupted to examine the effects of downstream 
paracrine signaling to osteoblasts. Osteocyte primary cilia formation was disrupted by IFT88 siRNA-mediated 
knockdown (A). Components of osteocyte primary cilia-mediated mechanotransduction were disrupted (B) by 
siRNA-mediated knockdown of AC6 (signal transduction), as well as PC2 and TRPV4 (cilia-localized 
mechanosensitive ion channels). In both conditions, impairment of osteocyte primary cilia-mediated 
mechanosensing abrogates pro-osteogenic paracrine signaling to osteoblasts. Mean ± SEM; n ≥ 4 for each group; *p 
< 0.05, ***p < 0.001. 
4.4.3. Fenoldopam treatment enhances intercellular signaling 
Finally, we examined how potentiating osteocyte mechanosensitivity may direct 
intercellular osteogenic signaling. Osteocytes were treated with fenoldopam to increase cilia 
length and enhance mechanosensitivity, and subjected to oscillatory fluid flow. The collected 
media was used to culture osteoblasts or MSCs for 24 or 48 hours, respectively. Media collected 
from the fenoldopam treated osteocytes significantly enhanced osteoblast osteogenic activity, as 
measured by osteopontin gene expression, and significantly enhanced MSC osteogenic 
differentiation, as measured by osterix (OSX) expression, Fig. 4.5. Additionally, we have 
previously demonstrated that HDAC6 (histone deacetylase 6) inhibition increases ciliary bending 
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stiffness to decrease mechanosensitivity 132. Osteoblasts cultured with conditioned media from 
mechanically stimulated osteocytes treated with the HDAC6 inhibitor, tubastatin, displayed 
impaired osteopontin expression, Fig. 4.5. 
 
 
Figure 4.5: Pharmacologically manipulating osteogenic intercellular communication 
Osteocytes were treated with fenoldopam, tubastatin, or vehicle control, and the resulting response of osteoblasts 
and MSCs was examined. Fenoldopam treatment sensitizes osteocyte mechanosensitivity to enhance mechanically-
stimulated pro-osteogenic paracrine signaling promoting osteoblast activity (A), and MSC osteogenic differentiation 
(B). Additionally, tubastatin treatment diminishes the flow-mediated osteocyte paracrine signaling to osteoblasts. 




In this work we have demonstrated that cilia, and cilia-associated proteins not only 
impact osteocyte mechanosensitivity, but the entire mechanotransduction cascade leading to pro-
osteogenic intercellular communication. By manipulating osteocyte mechanosensitivity, we can 
direct the intercellular signaling axis between cells within bone. 
Intercellular communication within bone utilizes several different paracrine factors to 
mediate osteogenic signaling. Mechanically stimulated osteocytes have been demonstrated to 
increase production of prostaglandin E2 and cAMP, as well as release of nitric oxide, Ca2+, and 
ATP 154,155. Expression of larger peptides involved in bone formation such as IGF-1, RANKL, 
and OPG have also been demonstrated to be increased in osteocytes exposed to physical 
stimulation 82,156. One major limitation of our model is that MLO-Y4 osteocytes do not produce 
sclerostin, a significant regulator of osteoblast activity 24,155. As previously described, sclerostin 
is produced by osteocytes as a negative regulator of osteoblast activity. Our results, however, 
demonstrate that sclerostin production by osteocytes is not exclusively necessary for the 
regulation of osteoblast activity by paracrine signaling.  
Paracrine signaling is not the sole method of intercellular communication. Osteocyte 
dendritic processes extend throughout the lacuno-canalicular network, allowing for direct cell 
contact between osteocytes, and other cells within bone. This allows for the formation of gap 
junctions between cells through which ions such as Na+, K+, Ca2+, and Mg2+ can be transported 
to neighboring cells 154. Connexins make up hemichannels which form gap junctions mediating 
intercellular signaling. In both osteocytes and osteoblasts connexin 43 (Cx43) has been 
demonstrated to open in response to fluid flow, enabling signal transduction between 
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neighboring cells 94. While our model does not recapitulate the entire complexity of bone, our 
data do demonstrate that manipulation of cellular mechanosensitivity can have profound impacts 
on pro-osteogenic intercellular signaling. 
By manipulating osteocyte primary cilia and ciliary associated proteins we can direct 
mechanically-induced intercellular communication. We have previously demonstrated that 
knockdown of AC6 impairs osteocyte mechanosensing, in a similar manner to impaired 
ciliogenesis by IFT88 knockdown 36,137. It has also been shown that polycystin 2 is involved in 
NO production in osteocytes exposed to oscillatory fluid flow 157. In vivo, skeletal deletion of the 
polycystin ion channel complex impairs whole bone mechanosensitivity 158. We have also 
demonstrated that knockdown of TRPV4 impairs osteocyte mechanosensing 35. TRPV4 has been 
implicated with a key role in cartilage mechanosensing, and mutations in this channel have been 
associated with numerous skeletal dysplasias 66,85. Interestingly our previous data suggests that 
TRPV4 and not PC2 is the main ciliary mechanosensitive ion channel over short periods of 
mechanical stimulation 35. TRPV4 and PC2, however, may form a heteromeric channel within 
the cilium suggesting that their function may in fact be linked, warranting further investigation 
into their long term ciliary mechanosensing function 159. Our data here also demonstrate that 
enhancing osteocyte primary cilia-mediated mechanosensing significantly potentiates pro-
osteogenic paracrine signaling to osteoblasts and MSCs. While osteoblasts and MSCs are 
certainly both mechanosensitive, the current paradigm is that osteocytes are the predominant 
mechanosensors within bone, directing osteogenic activity of other bone cells 154,160,161.   
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Chapter 5 
5. Targeting primary cilia to promote load-induced bone 
formation in vivo 
5.1. Abstract 
Bone actively responds to mechanical stimuli, yet none of the current treatment options 
for low bone mass and osteoporosis leverage the inherent mechanosensitivity of bone. Our group 
has previously identified the primary cilium as a critical mechanosensor within bone, and that 
pharmacologically targeting the primary cilium with fenoldopam can enhance osteocyte 
mechanosensitivity. In chapter 4, we demonstrate that potentiating osteocyte mechanosensing 
with fenoldopam in vitro promotes pro-osteogenic paracrine signaling to activate osteoblasts and 
stimulate osteogenic differentiation of mesenchymal stem cells. Here we utilize an in vivo model 
of load-induced bone formation to demonstrate that fenoldopam treatment sensitizes bone to 
mechanical stimulation, in a dose-dependent manner.  We then examine minimal adverse effects 
of this treatment as assessed by bone quality, and kidney and liver morphology and histology. 
Finally, we demonstrate that fenoldopam treatment can augment load-induced bone formation in 
osteoporotic bones, using a mouse model of postmenopausal osteoporosis. This work is the first 





As previously discussed in this thesis, osteoporosis is a devastating condition that 
contributes to increased risk of fracture and extended hospitalization, with over 50% of the US 
population over 50 years old having low bone mass leading to osteoporosis 162. It has long been 
known that bone actively responds to mechanical stimulation, with load being a potent anabolic 
stimulus of bone formation 163. Despite this, none of the current osteoporosis therapeutics 
leverage the inherent mechanosensitivity of bone. Bisphosphonates and RANKL inhibitors are 
antiresorptive agents that mitigate bone resorption, while the anti-sclerostin antibody prevents 
inactivation of bone-forming osteoblasts 15,164. Furthermore, these compounds are starting to be 
met with patient concern of increased microdamage with reports of mandibular necrosis and 
atypical fracture 17,18. Thus, the need for a new class of osteoporosis therapeutics is growing. 
Bone is known to actively respond to mechanical stimulation, with load being a potent 
anabolic stimulus of bone formation. Previous work from our group demonstrated that primary 
cilia play a key role in whole bone mechanosensitivity. When primary cilia are removed from 
osteocytes and osteoblasts using a DMP1-CRE Kif3A knockout mouse model, the animals 
display significantly attenuated load-induced bone adaptation 83. Furthermore, we have also 
shown that mice lacking the cilia-localized protein, adenylyl cyclase 6 (AC6) also display 
significantly diminished load-induced bone formation 86. Interestingly, these global AC6 
knockout animals display no alteration in normal bone development, suggesting a key role of 
AC6 in the response specifically to heightened mechanical stimuli.  
The work in this thesis suggests that primary cilia can be pharmacologically targeted to 
manipulate cellular mechanotransduction. We believe that increasing primary cilia length 
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increases the amount of ciliary membrane strain in response to mechanical stimulation, to further 
stimulate stretch-activated ion channels 137. However, it is also likely that increasing primary 
cilia length promotes production of ciliary proteins to potentiate mechanotransduction events. 
Dopamine-like 1 receptors localize to the primary cilium, and treatment with the agonist, 
fenoldopam, increases primary cilia length in endothelial cells, kidney epithelial cells, and 
osteocytes 56,102,137. Intravenous injection of fenoldopam lowers blood pressure in hypertensive 
patients and mice, by increasing flow-induced nitric oxide production 56. Furthermore, we 
previously identified in Chapter 2 that increasing primary cilia length with fenoldopam 
significantly enhances osteocyte mechanosensitivity and osteogenic signaling 137. Besschetnova 
et al. found that stimulating the cAMP/PKA signaling pathway increases primary cilia length, in 
an adenylyl cyclase-mediated manner 112. It has also been described that fenoldopam treatment 
increases adenylyl cyclase 6 production in human renal proximal tubule cells 118.  
Ovariectomized mice (OVX) are a commonly used estrogen depletion model simulating 
post-menopausal osteoporosis 165,166. OVX animals display significant changes in bone 
architecture such as decreased cortical thickness, decreased bone mineral density (BMD), and 
increased marrow area in cortical bone; as well as decreased bone volume fraction, trabecular 
number and thickness, and increased trabecular spacing in trabecular bone 166. Four weeks post-
ovariectomy in skeletally mature mice has been demonstrated to elicit an osteoporotic phenotype 
characterized by decreased bone volume fraction, trabecular spacing, trabecular number, and 
bone mineral density in trabecular bone; and decreased cortical thickness, bone mineral density, 
and increased marrow area in cortical bone 167. It has also been suggested that ovariectomy may 
lead to reduced mechanosensitivity of osteocytes 165. 
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Fenoldopam is a clinically approved treatment for patients with extreme hypertension 
but, until our recent in vitro work, has never been examined in the context of bone 137. The goal 
of the work in this chapter is to examine how fenoldopam affects whole bone mechanosensitivity 
to alter load-induced bone formation. Furthermore, we explore the potential of this cilia-targeted 
therapy to promote bone formation in osteoporotic animals. 
 
5.3. Materials and Methods 
5.3.1. Summary 
To study the potential of fenoldopam for use in promoting bone formation, we utilized a 
mouse model of compressive ulnar load to stimulate load-induced bone adaptation. Mice were 
subcutaneously injected with fenoldopam and subjected to mechanical stimulation. Periosteal 
bone formation was quantified in response to indicate drug-induced changes in whole bone 
mechanosensitivity. Potential adverse effects of drug treatment were also examined. 
5.3.2. Animals and injections 
16 week old, skeletally mature, C57Bl/6 mice were injected subcutaneously with 20 or 50 
mg/kg fenoldopam (US Pharmacopeal Convention), or vehicle control, for 7 consecutive days. 
Mice were housed in the Columbia University Barrier Facility and fed ad libidum. All 
procedures performed were in accordance with Columbia University Institutional Animal Care 
and Use Committee guidelines. 
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5.3.3. Mechanical stimulation, in vivo 
On the final three days of drug or control injection, animals were also subjected to 
compressive ulnar load at a peak load of 3 N using a 2 Hz sine wave for 120 cycles, as 
previously described 83,86. Contralateral limbs served as a non-loaded control. 2 days following 
load, mice were treated with 10 mg/kg calcein (Sigma), and 4 days later 70 mg/kg alizarin 
(Sigma), with mice being sacrificed 6 days later.  
5.3.4. Dynamic histomorphometry 
Dynamic histomorphometry was performed as previously described, measuring the 
amount and separation of calcein and alizarin labels to quantify mineralizing surface (rMS/BS), 
mineral apposition rate (rMAR), and bone formation rate (rBFR/BS) relative to non-loaded 
controls 83,86. Left and right ulnae were dissected and preserved in ethanol. Samples were then 
infiltrated with methyl methacrylate, and embedded in methyl methacrylate and benzoyl 
peroxide. Transverse sections of the ulnar midshaft were imaged on a laser scanning confocal 
microscope (Olympus Fluoview FV1000). Measurements of outer bone perimeter (OP), single 
label perimeter (SL), double label perimeter (DL), and double label area (DA) were made in 
ImageJ. The mineralizing surface relative to outer bone surface (MS/BS), mineral apposition rate 
(MAR), and bone formation rate (BFS/BS) were calculated as: 
MS/BS =  0.5 ∗ SL+ DLOP ∗ 100;  % MAR =  !"!" ∗ # of days between labels; µm per day BFR/BS =  !"#∗!"/!"!.!" ; µm3/µm2 per year 
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Relative measurements – rMS/BS, rMAR, rBFR/BS – were determined by subtracting non-
loaded from loaded ulnae to display differences due to mechanical load. 
5.3.5. mRNA expression 
For gene expression analysis, mice underwent the first 5 days of fenoldopam or vehicle 
injection, and 1 day of ulnar load. 24 hrs later mice were sacrificed, and ulnae were dissected, 
flash-frozen, and pulverized as previously described 155. Total mRNA was converted to cDNA 
by TaqMan reverse transcriptase (Applied Biosystems). Gene expression was analyzed by 
quantitative real-time PCR using primers and probes (Life Technologies) for analysis of adenylyl 
cyclase 6, Adcy6 (Mm00475772_m1), and GAPDH (4351309). Samples and standards were run 
in triplicate, and all gene expression was normalized to GAPDH endogenous control, as 
previously performed 137. 
5.3.6. Osteoporotic animals 
Ovariectomized (OVX) and Sham animals were purchased directly from Jackson 
Laboratories, with surgery performed at 12 weeks old. Mice followed the same injection (20 
mg/kg fenoldopam or vehicle control) and loading timepoints described above beginning at 16 
weeks old, a timeline previously demonstrated to exhibit an osteoporotic phenotype in mouse 
ulnae 167. Dynamic histomorphometry was only performed on OVX animals, while Sham 
animals were used to confirm osteoporotic phenotype based on µCT analysis. 
5.3.7. µCT analysis 
Non-loaded ulnae were used for µCT analysis. Samples were imaged with a Scanco 
ViaCT 80 at 10.5 µm isotropic resolution. Images were processed using a Gaussian filter and 
global threshold to segment bone volumes. Ulnar midshafts were imaged and used to assess 
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cortical bone, while the proximal epiphysis was used to examine ulnar trabecular bone. Cortical 
bone analysis was performed to determine total area, cortical area, marrow area, bone volume 
fraction (BV/TV), cortical thickness, moment of inertia (Imax and Imin), and bone mineral density 
(BMD). Trabecular analyses included BV/TV, connectivity density, trabecular number, 
trabecular thickness, trabecular spacing, and BMD. 
5.3.8. Kidney/Liver analysis 
Kidneys and liver were dissected from animals, weighed, fixed in 10% formalin, and 
stored in 70% ethanol before being paraffin embedded. 5 µm thick longitudinal sections were 
made, and samples were stained with hematoxylin and eosin to visualize tissue structure. Images 
were captured at 4X magnification. Kidney function was broadly examined by urine creatinine 
concentration. Mice were subcutaneously injected with 20 mg/kg fenoldopam 3 days per week 
(Monday, Wednesday, Friday) for 5 weeks, with urine collected once per week. Hydrophobic 
sand (Lab Sand) was used for urine sample collection, and analysis was performed using a total 
urine creatinine kit (Cayman Chemical). 
5.3.9. Analysis 
All data were analyzed with one-way ANOVA followed by Bonferroni post-hoc 
correction. Dynamic histomorphometry data were initially analyzed with 2-way ANOVA to 
determine no sex-based differences in drug-enhanced bone adaptation. Values are reported as 
mean ± SEM, with p < 0.05 considered statistically significant. Sample size, n, represents 




Figure 5.1: Injection and loading timeline 
16 week old mice were subcutaneously injected with fenoldopam (20 or 50 mg/kg) or vehicle control on 7 
consecutive days. On the final 3 days mice were also subjected to compressive ulnar loading. Schematic of mouse 
ulna placed between loading platens was adapted from Warden and Turner, Bone, 2004 168. 2 days following the 
completion of applied load, mice were injected with calcein, and then alizarin 4 days later. These fluorochrome 




5.4.1. Fenoldopam enhances load-induced bone formation 
First, we sought to translate our in vitro findings into an in vivo model of load-induced 
bone formation. Skeletally mature, 16 week old, mice were subcutaneously injected with 
fenoldopam (20 mg/kg or 50 mg/kg) or vehicle control for 7 consecutive days, Fig. 5.1. On the 
final 3 days, mice were also subjected to compressive ulnar load, while contralateral limbs 
served as non-loaded controls, as previously performed 86. Animals were then treated with 
calcein and alizarin 4 days apart to allow quantification of periosteal bone formation by standard 
dynamic histomorphometry 83,86, Fig. 5.2. The relative amount of mineralizing surface (rMS/BS) 
was quantified as the amount of labeled surface normalize to the bone surface. The mineral 
apposition rate (rMAR) is quantified by the separation of calcein and alizarin labels, while the 
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bone formation rate (rBFR/BS) is the product of rMS/BS and rMAR. While neither fenoldopam 
concentration elicited a significant increase in rMS/BS, 20 mg/kg fenoldopam results in a 
significant increase in rMAR and rBFR/BS compared to vehicle control, Fig. 5.3. Interestingly, 




Figure 5.2: Fluorochrome labels enable analysis of new bone formation 
Calcein (green) and alizarin (red) labels injected 4 days apart. Greater amounts of labeling around the periosteal 
surface of bone indicate increase mineralizing surface, while separation of labels indicates mineral apposition. 
Qualitatively, load greatly enhances bone formation, and fenoldopam treatment increases label separation. Scale bar 




Figure 5.3: Fenoldopam enhances load-induce bone adaptation 
Mice were treated with fenoldopam (20 mg/kg, or “Fen – High” at 50 mg/kg) for 7 consecutive days and also 
subjected to compressive ulnar load on the final 3 days. Fenoldopam treatment displayed no effect in enhancing the 
amount of mineralizing surface. However, the lower dose of fenoldopam (20 mg/kg) elicited significant increases in 
load-induced mineral apposition rate and bone formation rate. The higher dose of fenoldopam (50 mg/kg) had no 
effect on load-induced bone adaptation. Mean ± SEM; n = 26, 12, 14 for each group, respectively; ***p < 0.001. 
Male and female animals were grouped as 2-way ANOVA revealed no sex-based differences. All data are reported 
relative to non-loaded contralateral limbs.  
 
 
5.4.2. AC6 mRNA expression in ulnae 
Our previous work identified adenylyl cyclase 6 as a critical signal transduction protein 
in load-induced bone adaptation. Mice injected with 20 mg/kg fenoldopam for 5 days were 
sacrificed, and their ulnae were dissected for analysis of AC6 mRNA expression. In fact, the 
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effective dose of fenoldopam that enhances load-induced bone formation also elicited a 
significant increase in AC6 mRNA expression, Fig. 5.4. 
 
 
Figure 5.4: Fenoldopam enhances AC6 expression in ulnae 
Mice were treated with fenoldopam (20 mg/kg) for 5 days. 24 hours following the final injection mice were 
sacrificed and ulnae were dissected, flash frozen, and pulverized for mRNA analysis. Fenoldopam treatment 
increases AC6 mRNA expression in the ulnar cortical bone relative to vehicle control. Mean ± SEM; n = 8 for each 
group; **p < 0.01. 
 
5.4.3. Minimal adverse effects of fenoldopam treatment 
In addition to load-induced bone formation, we also examined potential indicators of 
adverse effects of drug treatment. Fenoldopam treatment elicited no qualitative change in bone 
ultrastructure, suggesting no difference in woven versus lamellar bone formed in response to 
load, Fig. 5.5. Additionally, µCT analysis revealed no difference in normal bone 
microarchitecture due to drug treatment, Fig. 5.5, Table 5.1. µCT was performed on ulna 
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midshaft to examine cortical bone at the region where dynamic histomorphometric 
measurements were taken. No changes in bone architecture were examined in 20 mg/kg 
fenoldopam treated animals, compared to vehicle control, Table 5.1. Kidney and liver weight 
was also assessed as an indicator of tissue inflammation, with no change examined relative to 
vehicle control, Fig. 5.6. Furthermore, no changes kidney and liver structure were observed, as 
assessed by H&E, Fig. 5.7. Urine creatinine was also examined over long-term drug treatment – 
3 days per week with 20 mg/kg fenoldopam for 5 weeks – and suggests no change in kidney 
function, Fig. 5.8. 
 
 
Figure 5.5: Examination of bone ultrastructure and microarchitecture 
Loaded ulnae from fenoldopam treated mice were examined for bone ultrastructure and microarchitecture. 
Representative images are shown. Left, Qualitative examination of the mid diaphysis of loaded ulnae suggest no 
changes in the quality of bone formed. Fenoldopam treatment enhanced load-induced bone formation, without 
promoting woven bone formation. Right, µCT analysis was performed on non-loaded ulnae to assess potential 




Table 5.1: Short-term fenoldopam treatment does not affect bone architecture 
The ulnar midshaft of non-loaded animals treated with 20 mg/kg fenoldopam was examined by µCT. Standard 
cortical bone parameters were examined. Fenoldopam treatment did not result in any change in bone architecture at 





Figure 5.6: Kidney and liver weights with fenoldopam 
The kidneys and liver were dissected from fenoldopam (50 mg/kg) treated animals and weighed relative to total 
body weight. Even at the higher dose of fenoldopam we see no change in kidney or liver weight. Mean ± SEM; n = 







Figure 5.7: Kidney and liver histology 
Kidneys and livers dissected from fenoldopam (50 mg/kg) treated animals were fixed, paraffin embedded, sectioned, 
and stained with H&E. The higher dose of fenoldopam does not cause any changes in tissue morphology compared 





Figure 5.8: Kidney function is not altered with fenoldopam 
Urine creatinine was assessed in animals treated with fenoldopam (20 mg/kg) 3 days per week for 5 weeks. Urine 
was collected at the same time once per week. After 5 weeks of drug treatment, there is no significant difference in 
urine creatinine concentration relative to pre-drug treatment values. Mean ± SEM; n = 7 for each group. 
 
 
5.4.4. Fenoldopam is efficacious in osteoporotic animals 
We next used ovariectomized (OVX) mice as an estrogen-deficiency model of post-
menopausal osteoporosis. Mice underwent OVX surgery at 12 weeks old. 4 weeks post surgery 
mice were injected with 20mg/kg fenoldopam for 7 days and subjected to compressive ulnar 
load. Fenoldopam treated animals displayed significantly augmented load-induced bone 
adaptation as measured by increased rMS/BS, rMAR, and rBFR/BS compared to vehicle control, 
Fig. 5.9. µCT was performed on ulnar cortical (mid diaphysis) and trabecular (proximal 
epiphysis) bone to confirm effects of OVX on ulnae microarchitecture, Table 5.2. 
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Figure 5.9: Fenoldopam enhances load-induced bone formation in osteoporotic animals 
Ovariectomy (OVX) was used as a model of post-menopausal osteoporosis. Mice were subjected to OVX surgery at 
12 weeks old, and fenoldopam (20 mg/kg) injections began at 16 weeks old. In osteoporotic animals, fenoldopam 
significantly enhances load-induced bone adaptation as quantified by dynamic histomorphometry. Mean ± SEM; n = 




Table 5.2: µCT analysis of osteoporotic and sham fenoldopam treated animals 
Non-loaded ulnae from OVX and Sham control animals were examined by µCT to assess bone microarchitecture. 
Statistical analyses were performed between OVX-Sham for either vehicle or fenoldopam treatment. (*) denotes 
values where OVX is significantly smaller compared to Sham counterpart. (+) denotes values where OVX is 
significantly higher compared to Sham counterpart. Data demonstrate that at this timepoint OVX animals display an 
osteoporotic phenotype with significantly lower bone volume fraction (bone vol. / total vol.) and bone mineral 
density, with increased marrow area in cortical bone. In trabecular bone OVX animals display significantly 
decreased bone volume fraction and bone mineral density, with decreased trabecular number and thickness, and 
increased trabecular spacing and structure model index (SMI). Mean ± SEM; */+ p < 0.05. 
 
5.5. Discussion 
Our results demonstrate that targeting primary cilia-mediated mechanosensing with 
fenoldopam treatment significantly enhances load-induced bone formation. While fenoldopam is 
clinically used for hypertension, this is the first work studying the effects of this treatment on 
bone in vivo. 
Our loading data suggests that short-term fenoldopam treatment does not affect normal 
bone architecture. µCT analysis of non-loaded cortical bone demonstrates no change in bone 
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physical properties after 7 days of fenoldopam injection. This treatment does, however, 
significantly enhance load-induced bone adaptation. Together this suggests that short-term 
fenoldopam treatment sensitizes cells to mechanical stimulation rather than eliciting long-term 
systemic changes in bone quality. This type of treatment could be used to sensitize bone to lower 
amounts of load, thus preventing progression of limited use-induced bone loss. Potential clinical 
application of fenoldopam to enhance bone formation would likely require an associated exercise 
regimen. 
It is not yet completely defined how fenoldopam treatment enhances primary cilia-
mediated mechanotransduction in bone, and it is likely a combination of both structural and 
biochemical changes. While in vitro we identify significant increases in cilia length, the limited 
lacunar space in which osteocytes reside may impede substantial cilia elongation 137. 
Computational models have suggested that specific orientations of primary cilia may allow for 
elongation leading to enhanced mechanosensitivity 92. This model also posits that osteocyte 
primary cilia may not be free standing organelles in vitro and may anchor to the lacunar wall, in 
a manner similar to chondrocyte cilia attaching to the extracellular matrix 63. Regardless of the 
means of physical changes to primary cilia structure, our data also demonstrates that fenoldopam 
treatment significantly enhances AC6 production. As previously described our recent work 
indicates that deletion of AC6 impairs load-induced bone formation, suggesting that the opposite 
may also be true, and that increasing AC6 production will augment load-induced bone formation 
86. Together the increase in cilia length, enabling further stimulation of stretch-activated ion 
channels, and enhanced AC6 protein levels potentiate bone mechanosensitivity. 
 87 
There is a therapeutic window in which fenoldopam treatment is effective in promoting 
load-induced bone formation. While 20 mg/kg fenoldopam significantly enhanced bone 
adaptation, 50 mg/kg elicited no bone formation response. Previous work identified that 
fenoldopam treatment increases primary cilia length in a dose-dependent manner 56. Moreover, 
when the concentration was increased to 2.5x the peak effective dose, cilia length reduces closer 
to baseline level. Currently it is not completely evident why this dose-dependence occurs, but it 
is likely due to toxicity. During injections with the higher dose of fenoldopam, we noticed a 
small amount of tissue necrosis near the injection site in several animals not experienced in with 
the effective, 20 mg/kg, dose. While this high dose may be associated with some level of 
toxicity, we do not examine any change in kidney or liver weight and morphology. Further 
toxicology would need to be performed to fully characterize adverse events. 
Fenoldopam does not specifically target osteocytes, thus allowing potential for adverse 
effects. While fenoldopam is clinically used to treat extreme hypertension, it resembles other 
antihypertensive compounds and has been shown to have limited or no effect hypotensive effect 
in normotensive patients 169,170. Furthermore, low enough doses of fenoldopam can still increase 
endothelial cilia length, and mechanically induced nitric oxide production, without affecting 
blood pressure 56. Fenoldopam treatment has, however, also been implicated with an increase in 
renal blood flow and an increase in natriuresis, diuresis, and glomerular filtration rate, potentially 
all leading to hypertensive renal damage and kidney disease 171. High enough doses of 
fenoldopam, 100 mg/kg, have also been found to be vasotoxic in a rat model 172. Our effective, 
20 mg/kg, treatment dose did not elicit any change in urine creatinine concentration, and even at 
our higher dose, 50 mg/kg, there was no change in kidney and liver weight or morphology. 
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Fenoldopam also does not cross the blood brain barrier, so there is minimal risk of dopaminergic 
central nervous system effects resulting from treatment 173. While primary cilia are not unique to 
osteocytes and fenoldopam does not specifically target bone, our data suggests minimal adverse 
systemic affects while still enhancing bone mechanosensitivity. A cell-type specific therapy 
would mitigate any concerns of adverse effects. 
Together, these data demonstrate that targeting the primary cilium is a potent strategy for 
directing cell mechanotransduction, and intercellular communication to dictate whole tissue 
function. This is the first demonstration of a ciliotherapy enhancing bone adaptation in vivo and, 
moreover, enhancing load-induced bone formation in osteoporotic subjects. Fenoldopam is 
clinically used, but until now has never been examined in the context of whole bone adaptation. 
Our results suggest that there is significant potential for repurposing fenoldopam for use in bone 
indications, and for developing cilia-targeted therapeutics to direct cell and tissue 






The overall goal of this thesis is to demonstrate the capability of targeting primary cilia to 
sensitize cells to mechanical stimulation and promote bone formation, as a potential therapeutic 
strategy for treating bone diseases. In this thesis we examined primary cilia-mediated 
mechanotransduction in osteocytes, expanded our list of candidate drugs through high-
throughput screening, studied implications of ciliary manipulations on intercellular pro-
osteogenic signaling, and translated this work into an in vivo model of bone formation in 
osteoporotic animals. This work elucidates primary cilia and mechanotransduction as viable 
targets for bone disease therapeutics. 
In Chapter 2, we demonstrated that two distinct compounds, fenoldopam and lithium, 
significantly increase primary cilia length. We then demonstrated that cells with longer cilia are 
more mechanosensitive. Furthermore, fenoldopam treatment was able to recover ciliogenesis in 
cells with disrupted cilia formation, and that this compound functions through a DR1-AC6-
cAMP-mediated pathway. The increase in cilia length is anticipated to enhance bending under 
fluid flow to further stimulate stretch-activated ion channels and also stimulate production of 
ciliary proteins such as AC6, together, potentiating mechanotransduction. 
In Chapter 3, we developed a high-throughput drug screening platform to further our list 
of candidate compounds that modulate ciliogenesis. 6931 compounds with known biologic 
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activity were tested for their capability to increase primary cilia length. We set up a fully 
automated platform to culture, drug treat, fix, stain, image, and analyze these compounds. Our 
analysis revealed 103 compounds that increase cilia length and 92 that increase cilia incidence, 
18 of which are conserved between both data sets. Because these compounds have known 
biologic activity, we classified these drugs based on mechanism of action to help further inform 
cilia biology research. 
In Chapter 4, we began to examine how manipulation of osteocyte primary cilia-mediated 
mechanotransduction may influence downstream osteogenic signaling to other cells within bone. 
We utilized a co-culture model where osteocytes underwent siRNA-mediated knockdown or 
pharmacologic challenge and were mechanically stimulated. The conditioned media was then 
used to culture osteoblasts or MSCs to study mechanically-induced paracrine signaling. We 
demonstrated that fenoldopam treatment not only enhances osteocyte mechanosensitivity, but 
also downstream signaling to promote osteoblast activity and MSC osteogenic differentiation. 
Finally, in Chapter 5, we translate our in vitro findings into an in vivo model of load-
induced bone formation. Mice treated with fenoldopam displayed significantly greater load-
induced bone formation, potentially occurring through an increase in AC6 production. 
Furthermore, we also utilized µCT to suggest that the increase in bone formation was 
predominantly due to enhanced mechanotransduction, and not changes in normal bone 
architecture due to drug treatment. We also began to examine potential adverse consequences of 
drug treatment, but did not see any alteration in quality of bone formed or serious signs of kidney 
or liver damage. Most importantly, we demonstrated that this treatment strategy also sensitizes 
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ovariectomized animal ulnae to mechanical stimulation, increasing load-induced bone formation 
in osteoporotic animals. 
 
6.2. Future studies 
The work in this thesis examines the therapeutic potential of targeting primary cilia-
mediated mechanosensing in promoting bone formation; yet, future work is required before this 
treatment strategy can be fully translated to human applications. 
To discern whether the increase in primary cilia-mediated mechanosensing is due to an 
increase in cilia bending or protein production, further work would need to be performed. Cells 
endogenously expressing SSTR3-GFP would enable visualization of cilia deflections in real 
time. Using our existing fluid flow devices and imaging capabilities we can compare ciliary 
bending between vehicle and drug treated cells 132,174. We can also couple this work with ciliary-
localized calcium and cAMP biosensors that our group has developed to elucidate changes in 
intraciliary signaling 35. 
Next, we plan to expand our drug screening efforts to further identify compounds that 
modulate ciliogenesis, and further elucidate signaling pathways involved in ciliogenesis. The 
drug screening platform can be expanded to include dose responses studies, as well as temporal 
responses. We only tested 10 µM concentrations for 16 hours. Previous work has demonstrated 
that higher concentrations of certain compounds can increase cilia length within 3 hours 112. 
Furthermore, our screen only included osteocytes. IMCD kidney epithelial cells are also 
commonly used to examine primary ciliogenesis. Growing work is also exploring the role of 
ciliogenesis in chondrocytes 175. Mimicking the same screening platform in kidney cells and 
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chondrocytes serves multiple purposes. Repeated classes of hits between cell types will 
demonstrate conserved pathways involved in ciliogenesis. Conversely, distinct individual and 
classes of compound will suggest cell type-specific effects, providing potential for minimal side 
effects with in vivo treatment. In the immediate future, we hope to perform confirmation studies 
to validate hits that increase cilia length, as well as incidence. 
Our co-culture experiments only examine paracrine signaling from osteocytes to 
osteoblasts and MSCs. Paracrine signaling is not the only means of intercellular communication, 
as direct-cell communication also plays a critical role in directing bone adaptation 94. While it is 
anticipated the enhanced osteocyte mechanosensing will also potentiate mechanotransduction 
events through direct-cell contact, further co-culture experiments could more accurately describe 
this pathway. In addition, the consequence of manipulating osteocyte mechanosensing on 
osteoclast activity would be a significant advance in this work as the majority of first-in-line 
osteoporosis treatments manipulate osteoclast activity. It is anticipated that enhanced osteocyte 
mechanosensitivity would limit, but not abolish, osteoclast activity. 
Finally, we wish to build upon our in vivo model of fenoldopam-sensitized bone 
formation. Numerous avenues exist to further test the therapeutic potential of this treatment 
strategy before it is ready for human trials. We only utilized subcutaneous injections, but oral 
delivery may provide a more patient-friendly alternative drug delivery mechanism. Long-term 
treatment and characterization of microdamage accumulation would allow for comparison 
between this treatment strategy and existing options. We have begun these long-term studies, 
treating ovariectomized and sham mice with fenoldopam for 5 weeks, and will examine 
trabecular and cortical bone architecture changes by µCT and bone strength with three-point 
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bending in response to prolonged drug treatment. We also plan to move to larger animal models, 
starting with rat, to establish efficacy in a more human physiologically relevant model. 
Currently, fenoldopam is only used in short doses, < 48 hours, in patients with extreme 
hypertension or renal failure. As such, no current patient data exists to infer potential 
implications on bone quality. Finally, expanding our drug screening efforts to include more 
compounds and multiple cell types will elucidate alternative compounds which may prove more 
efficacious or further reduce any potential adverse effects on other cell types. 
 
6.3. Significance 
Osteoporosis is a devastating condition affecting over 50 million Americans. The most 
significant consequence of osteoporosis is the severely heightened risk of fracture, with hip 
fractures being the most devastating at 20% patient mortality within the first year following 
fracture 3,4. Surviving patients are still left with dramatically impaired quality of life, with 60% 
requiring additional assistance, and 33% entirely reliant on caretakers, leaving less than 7% 
reaching full recovery 5,6. While current treatment options exist for conditions of low bone mass, 
there is increasing concern with these as risks of atypical fracture and necrosis emerge. As such, 
it is estimated that after one year only 40% of patients will continue with their prescribed 
treatment, and after two years only 20% will continue treatment 20,21. New therapeutic strategies 
are required. 
The work in this thesis is the first use of a cilia-targeted therapy to promote load-induced 
bone formation in osteoporotic bones. As mentioned, current osteoporosis therapeutics are 
targeted towards inhibiting normal bone pathways. Bisphosphonates and RANKL inhibitors 
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disrupt osteoclast-mediated resorption, while the anti-sclerostin antibody prevents osteoblast 
inactivation. Our results demonstrate that manipulation of bone mechanotransduction is a potent 
and viable strategy to promote bone formation. We believe that the primary cilium is not only a 
potential, but a viable and robust therapeutic target for manipulating cell mechanosensitivity and 
whole bone adaptation. This work opens the door to an entirely new class of bone disease 
therapeutics that leverage the inherent mechanosensitivity of bone to stimulate bone formation. 
Our proposed treatment strategy has the potential to enable patients to reap the benefits of mild 
ambulation to restore bone quality to slow and even treat the progression of osteoporosis. 
 While the work in this thesis focuses on the bone disease applications of targeting 
primary cilia, we believe that this work has significant implications in numerous human diseases. 
Mechanotransduction is a process critical to a wide range of cell and tissue types, and primary 
cilia are present on nearly every human cell type. Polycystic kidney disease, atherosclerosis, 
skeletal patterning, and osteoarthritis are all impacted by mechanotransduction. Furthering our 
understanding of how various cells sense and respond to mechanical cues, and elucidating ways 
to manipulate this process are critical in developing therapeutics for such a myriad of conditions. 
The impact of primary cilia and mechanotransduction are also increasingly being studied with 
regards to tumorigenesis. Breast and prostate cancer cells are known to lose primary cilia during 
tumorigenesis, and both cancer types engage in mechanotransduction, responding to changes in 
substrate stiffness through altered proliferation and migration 70,75,79. Recent work has even 
examined the potential role of mechanotransduction in bone metastasis 176–178. Manipulating 
primary ciliogenesis and mechanosensing may prove to be a therapeutic strategy for slowing 
tumorigenesis and metastasis. We believe that targeting primary cilia-mediated 
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mechanotransduction is a potent therapeutic strategy that has implications in the treatment of a 
wide range of significant human conditions.   
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